| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Rezpegaldesleukin (REZPEG, NKTR-358) Type 1 diabetes mellitus (new-onset T1D) — Phase 2 Trial (TrialNet collaboration) (program-level data timing) | Phase 2 | — | Subscribe to access the data. | Biologics | Endocrine System | |
Phase 2 data readout example | Rezpegaldesleukin (REZPEG, NKTR-358) Type 1 diabetes mellitus (new-onset T1D) — Phase 2 Trial (TrialNet collaboration) (program-level data timing) | Phase 2 | — | Subscribe to access the data. | Biologics | Endocrine System | |
Phase 2 data readout example | Rezpegaldesleukin (REZPEG, NKTR-358) Type 1 diabetes mellitus (new-onset T1D) — Phase 2 Trial (TrialNet collaboration) (program-level data timing) | Phase 2 | — | Subscribe to access the data. | Biologics | Endocrine System |
Recent Updates
Recently added Catalysts
Nektar Therapeutics
$74.86
-1.62 (-2.12%)
B 76Pipeline Score Undervalued Pharma · Clinical
Market Cap
2.53 B
EPS
-8.23
P/E Ratio
-
Value Trade
54.49 M
SEC Financials
Q1 2026Dilution Risk
Revenue
10.86 M
R&D Expenses
35.68 M
Operating CF
-44.30 M
Total Assets
763.27 M
Total Liabilities
187.06 M
Equity
576.22 M
2.89 %
Week
9.57 %
1 Month
-4.55 %
3 Month
33.68 %
6 Month
-75.8 %
5 Year
18.42 %
All Time
Cash Data
Cash Position
731.60 M
Monthly Burn
14.77 M
Runway
46.6 mo
Burn Trend
SEC Filing
May 8, 2026
Overview
Volume
486.88 K
52 Week Range
22.28 - 109
% held by Insiders
3.38 %
% held by Institutions
88.78 %
Enterprise Value
1.80 B
Total Shares
33.79 M
Short %
20.89 %
Float Shares
28.90 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Nektar Therapeutics
894Total events
13Upcoming
207Tier-1 (high impact)
2010 – 2029Coverage
Upcoming catalysts 2
TBD
T2Quarterly Update
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 2
TBD
▲Trial InitiationRezpegaldesleukinFiledTrial
Subscribe to view catalyst details
TBD
◆Trial InitiationRezpegaldesleukinFiledTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-03-31 | Rezpegaldesleukin | Phase 2b topline data readout | Phase 2b | — | – | – | – |
2026-03-31 | Rezpegaldesleukin | Phase 2b topline data readout | Phase 2b | — | – | – | – |
2026-03-31 | Rezpegaldesleukin | Phase 2b topline data readout | Phase 2b | — | – | – | – |
Drug Pipeline Intelligence
B76
Pipeline Score $19.0B
Pipeline ValueUndervalued
Valuation Signal14
Drugs Scored7.4x
rNPV / MCap Top 97%
Small Cap (rank 29 of 923)
Percentile RankNektar Therapeutics holds a solid B-grade pipeline (76/100), with $29.2B risk-adjusted pipeline value, led by NKTR-102 in Tumor (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NKTR-102 Small molecule | Locally Recurrent Breast Cancer | Phase 3 | NCT01492101 | 42% | $11.1B | COMPLETED | 852 | - | - | Jun 1, 2016 | - | Jun 1, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
rezpegaldesleukin Fast Track | severe-to-very-severe alopecia areata | Phase 2b | 2026-04-20 | SALT Score ≤20: low dose 29%, high dose 31%, placebo 0%; SALT Score ≤30: low dose 30.2%, high dose 35.0%, placebo 8.4%; p values: SALT Score ≤20 0.049, SALT Score ≤30 0.023; completion rate: 94% Read More | 52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin Read More | |
rezpegaldesleukin Fast Track | severe-to-very-severe alopecia areata | Phase 2b | 2026-04-20 | SALT Score ≤20: low dose 29%, high dose 31%, placebo 0%; SALT Score ≤30: low dose 30.2%, high dose 35.0%, placebo 8.4%; p values: SALT Score ≤20 0.049, SALT Score ≤30 0.023; completion rate: 94% Read More | 52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin Read More | |
rezpegaldesleukin Fast Track | severe-to-very-severe alopecia areata | Phase 2b | 2026-04-20 | SALT Score ≤20: low dose 29%, high dose 31%, placebo 0%; SALT Score ≤30: low dose 30.2%, high dose 35.0%, placebo 8.4%; p values: SALT Score ≤20 0.049, SALT Score ≤30 0.023; completion rate: 94% Read More | 52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NKTR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NKTR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-01-15 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2027-01-15 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2027-01-15 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NKTRNektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets
Nektar Therapeutics will announce its financial results for the second quarter of 2026 on August 13, 2026. The announcement will be followed by a conference call hosted by CEO Howard Robin at 5:00 p.m. ET. The call will be accessible via a webcast and will include a review of the company's performance and future plans.
Read more →NKTR▲ +5.9%on this news
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics has launched two global Phase 3 trials for rezpegaldesleukin, a novel T-cell biologic aimed at treating moderate-to-severe atopic dermatitis. The trials, ZENITH AD-1 and ZENITH AD-2, will enroll treatment-naive patients, while ZENITH AD-3 will focus on treatment-experienced patients. Initial data is expected by mid-2028, with a BLA submission targeted for 2029.
Read more →NKTRNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics (NASDAQ: NKTR) today announced that, on May 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors...
Nektar Therapeutics announced the granting of non-qualified stock options to five new employees under its 2025 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The stock options, totaling 11,900 shares, have an exercise price equal to the closing stock price on the grant date and will vest over four years. Nektar is focused on developing treatments for autoimmune and chronic inflammatory diseases and is currently involved in several clinical trials for their lead product candidate, rezpegaldesleukin, among others.
Read more →NKTRNektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
Nektar Therapeutics announced its participation in the 2026 Jefferies Global Healthcare Conference, scheduled for June 2-4, 2026, in New York. The company's management will host a webcast on June 3, 2026, at 1:20 p.m. ET, which will also be available for replay. Nektar is focused on developing treatments for autoimmune and chronic inflammatory diseases.
Read more →NKTRNektar Therapeutics Reports First Quarter 2026 Financial Results
Nektar Therapeutics reported its financial results for Q1 2026, highlighting a significant increase in cash and investments to $731.6 million. The company is preparing to advance its lead candidate, rezpegaldesleukin, into Phase 3 trials for atopic dermatitis and is seeing positive clinical responses in immune-mediated diseases. Despite a net loss of $44.9 million, the company remains well-positioned for future growth.
Read more →NKTRNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics (NASDAQ: NKTR) today announced that, on April 20, 2026, the Organization and Compensation Committee of Nektar's Board of...
Nektar Therapeutics announced the granting of non-qualified stock options and restricted stock units to six new hires under its 2025 Inducement Plan. This plan, designed to attract individuals not previously associated with the company, complies with Nasdaq Listing Rule 5635(c)(4). The stock options are priced at the current market value and are structured to vest over four years, encouraging employee retention. This strategic move indicates Nektar's commitment to expanding its talent pool as it continues to advance its clinical-stage pipeline.
Read more →NKTRNektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets
Nektar Therapeutics is set to announce its financial results for Q1 2026 on May 7, 2026. CEO Howard Robin will host a conference call at 5:00 p.m. ET to discuss the results. The call will be accessible via a webcast, which will be available for replay until June 7, 2026. Nektar is focused on developing treatments for autoimmune and chronic inflammatory diseases.
Read more →NKTRNektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Nektar Therapeutics has successfully closed a public offering, raising $373.8 million by selling 4,062,500 shares at $92.00 each. This includes the full exercise of the underwriters' option to purchase additional shares. The offering was conducted under a shelf registration statement and managed by Jefferies, TD Cowen, and Piper Sandler.
Read more →NKTRNKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Known Trial Defects: SueWallSt
A securities class action has been filed against Nektar Therapeutics due to alleged concealment of trial defects in the REZOLVE-AA Phase 2b trial. The lawsuit claims that Nektar's leadership misled investors about compliance with trial protocols, resulting in significant financial losses for shareholders. The company's stock price dropped sharply after the revelation of enrollment violations involving ineligible patients.
Read more →NKTR▼ -5.1%on this newsshared move
Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering
Nektar Therapeutics has announced the pricing of an upsized public offering, raising $325 million by selling 3,532,609 shares at $92.00 each. The offering is set to close on April 23, 2026, and aims to fund general corporate purposes, including clinical trials for its lead candidate, rezpegaldesleukin. The company has also granted underwriters an option to purchase additional shares.
Read more →NKTR▲ +18.3%on this newsshared move
52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin
Nektar Therapeutics announced positive results from the 16-week treatment extension of its Phase 2b REZOLVE-AA study, demonstrating that 29% and 31% of patients achieved significant hair growth with rezpegaldesleukin. The treatment maintained a favorable safety profile, with 94% of patients completing the study. These findings support the advancement of rezpegaldesleukin into late-stage development for severe alopecia areata.
Read more →NKTR▲ +18.3%on this newsshared move
Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026
Nektar Therapeutics will host a conference call on April 20, 2026, to discuss the 52-week topline results from the 16-week extension treatment period of its Phase 2b REZOLVE-AA study. The study evaluates rezpegaldesleukin for severe alopecia areata. The results will be shared via a press release and webcast, accessible to interested participants.
Read more →NKTR▲ +18.3%on this newsshared move
Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin 29% and 31% of patients in the 18 g/kg and 24
Nektar Therapeutics announced promising results from the 16-week blinded treatment extension of the REZOLVE-AA study, which evaluated rezpegaldesleukin for severe alopecia areata. A notable 29% of patients at the low dose and 31% at the high dose achieved new SALT Score 20 responses by week 52, reflecting meaningful hair growth. The safety profile remained consistent, with no patients discontinuing due to treatment-related adverse events. These results indicate the potential for rezpegaldesleukin to become a viable first-line treatment for this condition as the company plans to advance into late-stage development.
Read more →NKTR▲ +18.3%on this newsshared move
Nektar Therapeutics Announces Proposed Public Offering Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of...
Nektar Therapeutics has launched a public offering aiming to raise $250 million, which may include pre-funded warrants for certain investors. The proceeds are expected to support corporate needs, including significant clinical developments for its lead candidate rezpegaldesleukin. The offering is contingent upon market conditions, and underwriters have a 30-day option for additional shares. Nektar is navigating potential uncertainties related to market dynamics and is emphasizing its forward-looking statements indicating future plans.
Read more →NKTRNKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: Levi & Korsinsky
Nektar Therapeutics is facing a securities class action lawsuit due to alleged failures in patient enrollment standards for its Phase 2b REZOLVE-AA trial. The lawsuit claims that four ineligible patients were included in the trial, which compromised the study's primary endpoint. Nektar's stock dropped significantly following the disclosure of these issues, raising concerns about the integrity of its clinical trial processes.
Read more →NKTRData from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting
Nektar Therapeutics presented promising data on rezpegaldesleukin at the 2026 AAD Annual Meeting. The Phase 2b REZOLVE-AD study showed significant improvements in atopic dermatitis patients, while the REZOLVE-AA study demonstrated efficacy in alopecia areata. Nektar plans to initiate a Phase 3 program for atopic dermatitis in mid-2026.
Read more →NKTRData from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting
Nektar Therapeutics announced that data from its Phase 2b studies of rezpegaldesleukin for atopic dermatitis and alopecia areata have been accepted for oral presentations at the 2026 American Academy of Dermatology Annual Meeting. The presentations will detail efficacy and safety results from the studies. Rezpegaldesleukin is designed to restore immune balance in autoimmune conditions.
Read more →NKTRNektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Nektar Therapeutics reported its financial results for Q4 and full year 2025, highlighting a significant net loss and decreased revenue due to the sale of its manufacturing facility. Despite these challenges, the company announced successful Phase 2 data for its lead candidate, rezpegaldesleukin, and plans to initiate a Phase 3 program in atopic dermatitis. The company also reported a strengthened financial position following a recent secondary offering.
Read more →NKTRNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics (NASDAQ: NKTR) today announced that, on February 20, 2026, the Organization and Compensation Committee of Nektar's Board of...
Nektar Therapeutics (NASDAQ: NKTR) announced the grant of non-qualified stock options totaling 4,300 shares under its 2025 Inducement Plan to three newly-hired employees. The stock options, with an exercise price set at $73.73, will vest over four years contingent on continued employment. The plan is designed to enhance recruitment efforts according to Nasdaq Listing Rule 5635(c)(4). Nektar continues to focus on developing therapies for autoimmune and chronic inflammatory diseases, despite existing uncertainties in drug development.
Read more →NKTRNektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets
Nektar Therapeutics is set to announce its financial results for Q4 and the year ended December 31, 2025, on March 12, 2026. The announcement will follow the close of U.S. financial markets. CEO Howard Robin will lead a conference call to discuss the results, which will be accessible via a live webcast. Nektar continues to advance its pipeline of treatments for autoimmune and chronic inflammatory diseases.
Read more →NKTRNektar Therapeutics to Participate in Two Investor Conferences in March 2026
Nektar Therapeutics announced its participation in two upcoming investor conferences in March 2026. The TD Cowen 46th Annual Health Care Conference will take place in Boston from March 2-4, followed by the Jefferies Biotech on the Beach Summit in Miami from March 9-11. The presentations will be accessible online, and one-on-one meetings can be arranged.
Read more →NKTRNektar Therapeutics to Participate in Two Investor Conferences in March
Nektar Therapeutics announced its participation in two upcoming investor conferences in March 2026. The TD Cowen 46th Annual Health Care Conference will take place in Boston from March 2-4, while the Jefferies Biotech on the Beach Summit is scheduled for March 9-11 in Miami. The presentations will be accessible via webcast, and one-on-one meetings can be arranged with company management.
Read more →NKTRNektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis
Nektar Therapeutics has announced a research collaboration with UCSF and Dr. Stephen Hauser to explore NKTR-0165, a novel TNFR2 agonist antibody, for multiple sclerosis. This collaboration aims to investigate the potential neuroprotective effects of TNFR2 agonism in MS and other neurological conditions. Dr. Hauser's extensive experience in neuroimmunology is expected to advance the research significantly.
Read more →NKTRNektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis Nektar Therapeutics (Nasdaq: NKTR) today announced an academic research collaboration with the University of California, San Francisco (UCSF) and...
Nektar Therapeutics has announced a research collaboration with UCSF to explore NKTR-0165, a TNFR2 agonist antibody, for treating multiple sclerosis. The partnership aims to investigate the potential neuroprotective effects of TNFR2 agonism in MS models. Dr. Stephen Hauser will lead the research, which could advance treatment options for MS and other neurological conditions.
Read more →NKTRNektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Nektar Therapeutics has successfully closed a public offering, raising $460 million by selling shares of common stock and pre-funded warrants. The offering included the full exercise of the underwriters' option to purchase additional shares. This capital will aid in the development of Nektar's immunotherapy products, including its lead candidate for autoimmune diseases.
Read more →NKTR▲ +7%on this newsshared move
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering
Nektar Therapeutics has announced the pricing of its upsized public offering, raising $400 million through the sale of common stock and pre-funded warrants. The offering, which is set to close on February 13, 2026, will help fund research, development, and clinical trials for its drug candidates, including rezpegaldesleukin. The company has granted underwriters an option to purchase additional shares.
Read more →NKTR▲ +18.5%on this news· ran to +32% by day 3shared move
Nektar Therapeutics Announces Proposed Public Offering
Nektar Therapeutics has announced a public offering of $300 million in common stock and pre-funded warrants. The proceeds will support various corporate purposes, including clinical trials for its lead candidate, rezpegaldesleukin. The offering is subject to market conditions, and underwriters have a 30-day option to buy additional shares. The company aims to enhance its drug development efforts with the raised funds.
Read more →NKTR▲ +51.1%on this news· ran to +92% by day 3shared move
New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing
Nektar Therapeutics announced positive results from the REZOLVE-AD Phase 2b study of rezpegaldesleukin, showing significant efficacy in maintaining responses in patients with moderate-to-severe atopic dermatitis. The study demonstrated durable responses across key efficacy endpoints, with a favorable safety profile. The results support moving forward to a pivotal Phase 3 program.
Read more →NKTR▲ +51.1%on this news· ran to +92% by day 3shared move
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026
Nektar Therapeutics will host a conference call on February 10, 2026, to discuss topline results from the 36-week maintenance period of its Phase 2b REZOLVE-AD study. The trial investigates the efficacy of rezpegaldesleukin for moderate-to-severe atopic dermatitis. Results will be shared via a press release and a live webcast.
Read more →NKTRNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Therapeutics announced the granting of stock options to a new employee under its 2025 Inducement Plan. The options, totaling 1,600 shares, have an exercise price of $36.92 and will vest over four years. This initiative is part of Nektar's strategy to attract talent and is compliant with Nasdaq Listing Rule 5635(c)(4).
Read more →NKTR▼ -7.8%on this news
REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata
Nektar Therapeutics announced positive topline results from the Phase 2b REZOLVE-AA trial of rezpegaldesleukin, showing significant reductions in SALT scores for patients with severe-to-very-severe alopecia areata. The treatment was well tolerated, and results support moving into Phase 3 development. A conference call will discuss these findings further.
Read more →NKTR▼ -7.8%on this newsshared move
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025
Nektar Therapeutics will hold a conference call on December 16, 2025, to discuss topline results from the 36-week induction treatment period of its Phase 2b REZOLVE-AA study. The study evaluates rezpegaldesleukin, a Treg proliferator, for treating severe alopecia areata. The results will be shared via a press release and webcast.
Read more →NKTRNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 5, 2025
Nektar Therapeutics announced the grant of non-qualified stock options to two new employees as part of its 2025 Inducement Plan. This plan, adopted to attract talent, allows for equity awards to individuals not previously associated with the company. The stock options have varying exercise prices and vesting schedules, aimed at fostering employee retention.
Read more →NKTRNew Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
Nektar Therapeutics presented new data from the REZOLVE-AD Phase 2b study at the ACAAI 2025 meeting, showing significant improvements in asthma control and atopic dermatitis symptoms with rezpegaldesleukin. The treatment demonstrated efficacy across multiple endpoints, including ACQ-5 scores and EASI metrics, supporting its advancement into Phase 3 studies. Long-term data is expected in Q1 2026.
Read more →NKTRNektar Therapeutics Reports Third Quarter 2025 Financial Results
Nektar Therapeutics reported its third-quarter 2025 financial results, revealing a cash position of $270.2 million. The company highlighted progress with rezpegaldesleukin, which is showing promise in treating moderate-to-severe atopic dermatitis. However, revenue has decreased significantly compared to the previous year, primarily due to the sale of its Huntsville manufacturing facility, leading to ongoing net losses.
Read more →NKTRNektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Nektar Therapeutics announced its participation in the Jefferies Global Healthcare Conference in London from November 17-20, 2025. The event will feature a webcast of a fireside chat with company management. Investors can also request one-on-one meetings during the conference. Nektar is focused on developing treatments for autoimmune and chronic inflammatory diseases.
Read more →NKTRNektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets
Nektar Therapeutics will announce its third-quarter financial results on November 6, 2025, after U.S. markets close. CEO Howard Robin will lead a conference call to discuss the results at 5:00 p.m. ET. The call will be accessible via the company's website and available for replay until December 6, 2025.
Read more →NKTRData from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting Nektar Therapeutics (Nasdaq: NKTR) announced today that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway...
Nektar Therapeutics announced that new data from its Phase 2b REZOLVE-AD study of rezpegaldesleukin has been accepted for a late-breaking oral presentation at the ACAAI Annual Meeting 2025. The study involves moderate-to-severe atopic dermatitis patients and tests the efficacy and safety of rezpegaldesleukin, an IL-2 pathway agonist. The meeting will take place in Orlando from November 6 to 10, 2025, where findings will be shared. The FDA has previously granted Fast Track designation for rezpegaldesleukin for atopic dermatitis and alopecia areata.
Read more →NKTR▲ +15.1%on this news
Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025
Nektar Therapeutics presented promising data from the REZOLVE-AD Phase 2b study of rezpegaldesleukin at the EADV Congress 2025. The study met its primary endpoint, showing significant improvement in eczema severity at week 16. Additionally, interim data indicated enhanced responses for patients who transitioned from placebo to treatment, suggesting the potential of rezpegaldesleukin in managing atopic dermatitis.
Read more →NKTR▲ +15.1%on this newsshared move
Efficacy and Safety of Rezpegaldesleukin, A Selective Regulatory T - Cell - Inducing Interleukin - 2 Conjugate, in the Treatment of Atopic Dermatitis: Final Results from the 16 - Week Induction of a Randomized Phase 2b S
The article discusses the final results of a Phase 2b study (REZOLVE-AD) for Rezpegaldesleukin, a novel interleukin-2 conjugate, in the treatment of moderate-to-severe atopic dermatitis. The study's 16-week induction phase demonstrated promising efficacy and safety, indicating that Rezpegaldesleukin can enhance regulatory T cell activity, thereby restoring immune balance in affected patients. The drug was awarded Fast Track designation, facilitating its development for those whose conditions are not adequately managed with existing therapies.
Read more →NKTR▲ +9.6%on this news
Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 Nektar Therapeutics (Nasdaq: NKTR) announced today that it will present results from the ongoing REZOLVE-AD Phase 2b study at the 2025 European...
Nektar Therapeutics announced it will present results from the REZOLVE-AD Phase 2b study at the 2025 EADV Congress in Paris. The presentation will detail data from a 16-week induction phase, including outcomes from patients initially on placebo who transitioned to high-dose rezpegaldesleukin. The drug is being evaluated for treating moderate-to-severe atopic dermatitis and previously received Fast Track designation from the FDA. This highlights the company's ongoing commitment to develop therapies for autoimmune and inflammatory conditions.
Read more →NKTR▲ +26%on this news· ran to +70% by day 3shared move
Nektar Therapeutics to Participate in Two Investor Conferences in September
Nektar Therapeutics will participate in two investor conferences in September 2025. The H.C. Wainwright 27th Annual Global Investment Conference will take place from September 8-10 in New York City, followed by the Stifel Virtual Immunology and Inflammation Forum on September 15-16. Presentations will be webcasted and available for replay for 30 days.
Read more →NKTRNektar Therapeutics Reports Second Quarter 2025 Financial Results Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2025. Cash and investments in marketable...
Nektar Therapeutics reported its financial results for Q2 2025, revealing a cash position of $175.9 million. The company highlighted positive data from its Phase 2b study of rezpegaldesleukin for atopic dermatitis and received Fast Track designation from the FDA for alopecia areata. However, revenue has decreased year-over-year, leading to a net loss of $41.6 million.
Read more →NKTRNektar Therapeutics Reports Second Quarter 2025 Financial Results
Nektar Therapeutics announced its financial results for Q2 2025, revealing a revenue decline to $11.2 million, influenced by the sale of its Huntsville manufacturing facility. Notably, the company highlighted promising Phase 2b data for its drug rezpegaldesleukin targeting atopic dermatitis. Nektar also expects its cash reserves to sustain operations into early 2027, despite a net loss of $41.6 million. Management is optimistic about upcoming clinical trials and new treatment programs in their pipeline, looking to innovate in the autoimmune disorder space.
Read more →NKTRNektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 7, 2025, after the close of...
Nektar Therapeutics will announce its financial results for the second quarter of 2025 on August 7, 2025, following the close of U.S. financial markets. Howard Robin, the company's CEO, will host a conference call at 5:00 p.m. Eastern Time to discuss the results. The event will be accessible via a web broadcast on Nektar's website, with a replay available until September 7, 2025. Nektar is a clinical-stage biotechnology company focused on developing innovative treatments for autoimmune and chronic inflammatory diseases.
Read more →NKTRNektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for...
Nektar Therapeutics has received Fast Track designation from the FDA for its investigational therapy, rezpegaldesleukin, aimed at treating severe-to-very severe alopecia areata. This designation facilitates a more expedited development process, enhancing the therapy's potential to reach patients quickly. The REZOLVE-AA Phase 2b study is currently underway, with topline data expected to be announced in December 2025. Rezpegaldesleukin represents a novel approach to addressing immune system imbalances underlying autoimmune conditions.
Read more →NKTRNektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of...
Nektar Therapeutics has successfully closed a public offering raising $115 million by selling nearly 4.9 million shares at $23.50 each. The funds raised will support the company's general corporate purposes, including ongoing research and development for its innovative drug candidates. The offering also saw the full exercise of an option by underwriters to purchase additional shares, emphasizing market confidence in Nektar's prospects. Joint managers Jefferies and Piper Sandler led the offering.
Read more →NKTRNektar Therapeutics Announces Pricing of $100 Million Public Offering
Nektar Therapeutics has announced the pricing of a $100 million public offering of its common stock, with shares being sold at $23.50 each. The offering, which consists of 4,255,320 shares, is set to close on July 2, 2025, pending customary conditions. Nektar intends to use the proceeds for general corporate purposes, including research and development and clinical costs related to its drug pipeline. Additionally, there is a 30-day option for underwriters to purchase an extra 638,298 shares.
Read more →NKTRNektar Therapeutics Announces Pricing of $100 Million Public Offering Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of...
Nektar Therapeutics has announced the pricing of its public offering, aiming to raise $100 million by selling 4,255,320 shares at $23.50 each. The proceeds will be used for general corporate purposes, including research and development. The offering is set to close on July 2, 2025, pending customary conditions.
Read more →NKTR▲ +156.3%on this news· ran to +205% by day 1
REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis Achieved statistical significance on primary endpoint at week 16 for mean per
Nektar Therapeutics announced positive results from the Phase 2b REZOLVE-AD study of rezpegaldesleukin for moderate-to-severe atopic dermatitis. The study achieved statistical significance for the primary efficacy endpoint of the Eczema Area and Severity Index (EASI) and several key secondary endpoints, indicating meaningful improvement in skin condition and itch relief. The treatment demonstrated a favorable safety profile, with the most common adverse events being mild local injection reactions. These findings support rezpegaldesleukin's potential as a leading immune-modulator in dermatological applications.
Read more →NKTR▲ +156.3%on this news· ran to +205% by day 1
REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis Achieved statistical significance on primary endpoint at week 16 for mean percent change in EASI score from baseline for all rezpegaldesleukin arms...
Nektar Therapeutics announced positive results from the Phase 2b REZOLVE-AD study of rezpegaldesleukin, showing significant improvements in Eczema Area and Severity Index (EASI) scores at week 16 compared to placebo. All dose arms met primary and key secondary endpoints, indicating rapid itch relief and disease reduction. The safety profile was consistent with prior studies, with mostly mild adverse events reported. Further data from the long-term maintenance phase is expected in Q1 2026.
Read more →NKTR▲ +12.1%on this news· ran to +249% by day 3shared move
Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025 Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it...
Nektar Therapeutics has announced that it will host an investor call to review top-line data from the 16-week induction period of its Phase 2b REZOLVE-AD clinical trial. This trial examines rezpegaldesleukin, a T-cell proliferator, for treating moderate-to-severe atopic dermatitis. The event is scheduled for June 24, 2025, and details will be available through a morning press release and on the company's website. A replay of the presentation will also be accessible for at least 30 days post-event.
Read more →NKTRNektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual BioConnect ...
Nektar Therapeutics has announced that it will be webcasting its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025. The event will be held at the Nasdaq Headquarters in New York City. Investors will have the opportunity to engage with company management through one-on-one meetings, which may enhance investor relations. Nektar's innovative pipeline includes treatments for various autoimmune diseases and cancer.
Read more →NKTRNektar Therapeutics Reports First Quarter 2025 Financial Results
Nektar Therapeutics reported its first quarter 2025 financial results, revealing a revenue decrease due to the sale of its manufacturing facility. Cash reserves stood at $220.7 million, projected to sustain operations into late 2026. The company aims to present topline data from two Phase 2 studies of the drug rezpegaldesleukin in the coming months. However, the net loss increased compared to the previous year, highlighting ongoing financial challenges.
Read more →NKTRNektar Therapeutics Reports First Quarter 2025 Financial Results Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2025. Cash and investments in marketable...
Nektar Therapeutics reported its financial results for Q1 2025, showing a decrease in revenue to $10.5 million compared to $21.6 million in Q1 2024. The company is preparing to release topline data from two Phase 2 studies of rezpegaldesleukin, with significant cash reserves expected to support operations until late 2026. However, the net loss has increased to $50.9 million, influenced by a non-cash loss from an equity investment.
Read more →NKTRNektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 8, 2025, after the close of U.S.-based...
Nektar Therapeutics will announce its financial results for the first quarter on May 8, 2025, after U.S. markets close. CEO Howard Robin will host a conference call at 5:00 PM ET to discuss the results. Investors can pre-register for the call and access a live audio webcast. Nektar Therapeutics focuses on developing treatments for autoimmune and chronic inflammatory diseases, with several candidates in clinical trials.
Read more →NKTRNektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune ...
Nektar Therapeutics has announced its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference, where it will webcast a fireside chat. The presentation will also be made available for replay for 30 days on the company's investor events webpage. Nektar focuses on developing treatments for autoimmune and chronic inflammatory diseases, with its lead product candidate undergoing Phase 2b clinical trials. The company's innovative pipeline also includes various other upcoming therapies in development.
Read more →NKTRNektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash and investments in...
Nektar Therapeutics reported its financial results for Q4 and full year 2024, showing a net income of $7.3 million for the quarter, a significant improvement from a loss of $42.1 million in Q4 2023. The company highlighted advancements in its immunology pipeline, with two Phase 2b trials nearing data milestones in 2025. However, the overall net loss for the year was $119 million, indicating ongoing financial challenges.
Read more →NKTRNektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Nektar Therapeutics reported financial results for Q4 and full year 2024, highlighting a revenue increase to $29.2 million in Q4 from $23.9 million in the previous year. The company has completed enrollment for its Phase 2b trials focused on atopic dermatitis and alopecia areata. Nektar anticipates key data releases in 2025, while also noting a significant reduction in operating costs and an improved net loss compared to 2023. However, the overall net loss remains considerable, reflecting ongoing financial challenges.
Read more →NKTRNektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2024 on Wednesday, March...
Nektar Therapeutics will announce its financial results for the fourth quarter and year ending December 31, 2024, on March 12, 2025. CEO Howard Robin will lead a conference call to discuss the results at 5:00 p.m. ET. Interested parties can access the call through pre-registration, with a replay available until April 12, 2025. The company is known for developing treatments for autoimmune and chronic inflammatory diseases.
Read more →NKTR▼ -10.4%on this news
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin...
Nektar Therapeutics has completed the target enrollment of 84 patients in its REZOLVE-AA Phase 2b clinical trial for rezpegaldesleukin, aimed at treating severe-to-very severe alopecia areata. Rezpegaldesleukin is designed to stimulate regulatory T cells to address immune system dysfunction affecting hair follicles. The trial began in March 2024 and encompasses patients who have not received a JAK inhibitor or other biologic therapies. Nektar plans to report topline data in the fourth quarter of 2025, highlighting the high unmet need for effective treatments in this condition.
Read more →NKTR▼ -9.4%on this newsshared move
Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus Nektar Therapeutics (Nasdaq: NKTR) and TrialNet, an international clinical trial network at the forefront of diabetes research, today announced a new ...
Nektar Therapeutics has partnered with TrialNet to conduct a Phase 2 clinical trial evaluating rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus. The trial will assess the safety and efficacy of the treatment in approximately 70 participants. The study aims to preserve beta-cell function and improve glycemic control over a 12-month period.
Read more →NKTR▼ -9.4%on this newsshared move
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event with Type 1 Diabetes (T1D) Experts on...
Nektar Therapeutics has announced a virtual investor and analyst event scheduled for February 24, 2025, featuring discussions with leading experts in Type 1 Diabetes. The event will address the company's investigational product, rezpegaldesleukin, which has received Fast Track designation from the FDA for the treatment of moderate-to-severe atopic dermatitis. Rezpegaldesleukin aims to target immune system imbalances related to autoimmune diseases. However, the development of the drug faces significant risks and uncertainties that could impact its clinical trial outcomes and regulatory approval timelines.
Read more →NKTR▼ -9.4%on this newsshared move
Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus -- TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study -- SAN FRANCISC
Nektar Therapeutics has entered into a clinical trial agreement with TrialNet to assess the efficacy of its drug rezpegaldesleukin in patients with newly diagnosed type 1 diabetes mellitus. This Phase 2 randomized, placebo-controlled study aims to evaluate the drug's safety and possible benefits in approximately 70 participants, involving a mixed meal tolerance test over a 12-month period. Although the initiative presents an opportunity to advance treatment for type 1 diabetes, it also carries the usual risks associated with clinical trials.
Read more →NKTRNektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for...
Nektar Therapeutics has announced that the FDA has granted Fast Track designation for its investigational drug, rezpegaldesleukin, aimed at treating moderate-to-severe atopic dermatitis. This designation facilitates quicker communication with the FDA and prioritization in the drug development process. Rezpegaldesleukin has shown promising early efficacy in clinical studies, and topline data from the Phase 2b REZOLVE-AD study is expected soon. The drug aims to improve the lives of patients with significant unmet needs in atopic dermatitis management.
Read more →NKTR▼ -9.6%on this news· ran to -21% by day 3
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AD Phase 2b study of rezpegaldesleukin...
Nektar Therapeutics has announced the completion of target enrollment for its REZOLVE-AD Phase 2b clinical trial of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. The study, which involved 396 patients, aims to evaluate the drug's effectiveness as a first-in-class interleukin-2 receptor agonist. The company is looking forward to releasing topline data by the second quarter of 2025. While the current results are promising, they remain subject to the uncertainties associated with clinical trials.
Read more →NKTRNektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting Nektar Therapeutics (Nasdaq: NKTR) today announced results of its Phase 2 proof-of-concept study evaluating NKTR-255 as an adjuvant treatment to...
Nektar Therapeutics presented the results of a Phase 2 proof-of-concept study for NKTR-255, which serves as an adjuvant treatment to improve outcomes for patients with relapsed or refractory large B-cell lymphoma undergoing CD19-directed CAR-T therapy. The study, reported at the ASH Annual Meeting, showed a complete response rate of 73% in the treatment group, compared to 50% in the placebo group. NKTR-255 demonstrated a notable enhancement in CAR T-cell kinetics and was reported to be safe and well-tolerated. These findings suggest a promising potential for NKTR-255 in bolstering CAR-T therapy effectiveness.
Read more →NKTRNektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence Nektar Therapeutics (Nasdaq: NKTR) today announced its oral presentation highlighting preclinical data on NKTR-422 at the 2024 American College of...
Nektar Therapeutics has announced promising preclinical data for its novel drug NKTR-422, aimed at addressing chronic inflammation. Presented at the 2024 ACR Convergence, the data suggests that NKTR-422 facilitates inflammation resolution and tissue repair in preclinical models. Unlike existing therapies, NKTR-422 offers a unique pharmacokinetic profile that may enhance treatment efficacy and improve disease remission. However, the drug is still in preclinical stages, and its ultimate success will depend on future clinical trial outcomes.
Read more →NKTRNektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) and collaborators at The University of Texas MD Anderson Cancer Center today presented late-breaking results from...
Nektar Therapeutics and MD Anderson Cancer Center presented results from a Phase 2 study of NKTR-255, which showed significant lymphocyte recovery in lung cancer patients after chemoradiation. The study indicated that NKTR-255 could enhance the recovery of immune cells, particularly when combined with durvalumab. This finding suggests potential prognostic benefits for patients suffering from radiation-induced lymphopenia associated with non-small cell lung cancer. The ongoing trial aims to assess the safety and efficacy of NKTR-255 in improving patient outcomes.
Read more →NKTRNektar Therapeutics Reports Third Quarter 2024 Financial Results Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2024. Cash and investments in...
Nektar Therapeutics reported its financial results for Q3 2024, showing a net loss of $37.1 million. The company highlighted advancements in its immunology pipeline, particularly with rezpegaldesleukin in atopic dermatitis and alopecia areata. Enrollment in these Phase 2b studies is progressing well, with topline data expected in 2025. Additionally, Nektar announced a sale of its PEGylation manufacturing business for $90 million.
Read more →NKTRNektar Therapeutics Reports Third Quarter 2024 Financial Results
Nektar Therapeutics reported its financial results for the third quarter of 2024, highlighting a continued focus on its immune and inflammatory pipeline. The company is advancing its lead candidate, rezpegaldesleukin, with ongoing Phase 2b studies and rapid enrollment in atopic dermatitis and alopecia areata trials. Despite reporting an improved quarterly net loss compared to the previous year, the company has acknowledged decreasing operating costs, driven by restructuring and reduced expenses. Nektar is also preparing to present new data at several key medical meetings in the coming weeks.
Read more →NKTRNektar Therapeutics to Participate in Upcoming Investor Conferences Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the upcoming conferences: UBS Global...
Nektar Therapeutics has announced its participation in upcoming investor conferences, where the company will be webcasting its presentations. The webcasts will be accessible on the Nektar website, and replays will be available for 30 days. Attendees interested in one-on-one meetings with company management can request them through their bank representatives.
Read more →NKTR▲ +8.1%on this newsshared move
FINAL CONFIDENTIAL PRESS RELEASE FOR ISSUANCE MONDAY NOVEMBER 4, 2024 AT 5:30AM PT, 7:30 AM CT Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing
Nektar Therapeutics has entered a definitive agreement to sell its Huntsville, Alabama PEGylation reagent manufacturing business to Ampersand Capital Partners for $90 million. The transaction, composed of $70 million in cash and $20 million in equity, allows Nektar to streamline operations and focus on its core R&D in immunology. The sale is expected to close by December 2, 2024, with all Huntsville employees offered jobs at the new standalone company, which aims to ensure a reliable supply of PEGylation reagents for Nektar's ongoing needs.
Read more →NKTR▲ +8.1%on this newsshared move
Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune...
Nektar Therapeutics has finalized an agreement with Ampersand Capital Partners to sell its Huntsville, Alabama manufacturing facility and PEGylation reagent business for $90 million. The agreement includes $70 million in cash and $20 million in equity ownership of the new Ampersand portfolio company. This strategic divestiture allows Nektar to streamline operations and concentrate on its research and development in immunology, particularly for its pipeline programs. The existing workforce at the facility will be retained to maintain manufacturing quality. The sale is anticipated to close by December 2, 2024.
Read more →NKTRNektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2024 on Thursday, November 7, 2024, after the close of U....
Nektar Therapeutics will announce its financial results for Q3 2024 on November 7, 2024, after the close of U.S. markets. The announcement will be followed by a conference call hosted by CEO Howard Robin to review the results. Investors can access the press release, the conference call, and the subsequent replay details through the company's website. This event demonstrates Nektar's commitment to keeping stakeholders informed about its financial performance.
Read more →NKTR▼ -6.6%on this newsshared move
Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases Nektar Therapeutics (Nasdaq: NKTR), today announced the publication of peer-reviewed data from two Phase 1b studies in Nature Communications...
Nektar Therapeutics announced the publication of peer-reviewed results from two Phase 1b studies in Nature Communications, highlighting the promising efficacy of rezpegaldesleukin, a first-in-class interleukin-2 receptor agonist, for treating atopic dermatitis and psoriasis. The studies demonstrated dose-dependent improvements in disease activity and patient-reported outcomes, with sustained benefits lasting at least 36 weeks post-treatment. The findings support the Treg hypothesis and indicate that rezpegaldesleukin can address multiple pathways involved in chronic inflammatory skin diseases. Nektar looks forward to additional results from upcoming Phase 2b studies.
Read more →NKTR▲ +5.1%on this news
Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of the first clinical data from a Phase 1 study evaluating NKTR-255 in combination ...
Nektar Therapeutics announced the publication of Phase 1 clinical data for its IL-15 agonist NKTR-255 combined with CD19-22 CAR-T cell therapy targeting B-cell acute lymphoblastic leukemia (B-ALL). The study, published in the journal Blood, showed an impressive 67% relapse-free survival rate at 12 months, indicating significant therapeutic potential. Eight out of nine patients treated achieved complete remission with no detectable minimal residual disease. The findings suggest NKTR-255 significantly enhances the effectiveness of CAR-T therapies, addressing a critical unmet need in B-ALL treatment.
Read more →NKTRNektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024 Nektar Therapeutics (Nasdaq: NKTR) today announced several presentations for rezpegaldesleukin (REZPEG) at the 2024 European Academy of Dermatology...
Nektar Therapeutics announced multiple presentations for its drug rezpegaldesleukin (REZPEG) at the 2024 EADV Congress. The findings highlighted the drug's unique proteomic profile and immunoregulatory effects in patients with atopic dermatitis. REZPEG aims to stimulate regulatory T cells while avoiding activation of cytotoxic T cells, addressing immune imbalance in autoimmune conditions. Upcoming topline data from Phase 2b studies in both atopic dermatitis and alopecia areata are expected in 2025, which could enhance understanding of REZPEG's efficacy and potential impact on treatment practices.
Read more →NKTRNektar Management to Present at Upcoming Investor Conferences Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment ...
Nektar Therapeutics (Nasdaq: NKTR) has announced that its management will present at various investor conferences in the near future. The presentations will be accessible through webcasts, allowing for broader investor engagement. These webcasts will remain available for replay for a specified time, indicating Nektar's commitment to transparency and communication with stakeholders.
Read more →NKTRNektar Therapeutics Reports Second Quarter 2024 Financial Results Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2024. Cash and investments in marketable...
Nektar Therapeutics reported its financial results for Q2 2024, showing a revenue increase to $23.5 million. The company maintains a strong cash position of $290.6 million, supporting operations through 2026. Nektar is advancing its drug candidates, with positive Phase 2 study progress for rezpegaldesleukin and promising data for NKTR-255. However, the company continues to face significant net losses and high operating costs.
Read more →NKTRNektar Therapeutics Reports Second Quarter 2024 Financial Results
Nektar Therapeutics announced its second quarter 2024 financial results, revealing a cash position of $290.6 million, sufficient to support development activities until 2026. The company is advancing its lead product candidate rezpegaldesleukin in Phase 2 studies related to atopic dermatitis and alopecia areata, with topline data expected in the first half of 2025. While Nektar saw a year-on-year increase in revenue, it also reported a net loss of $52.4 million for the quarter, partly due to substantial impairment charges linked to the San Francisco commercial real estate market.
Read more →NKTR▼ -5.2%on this news
Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2024 on Thursday, August 8, 2024, after the close of...
Nektar Therapeutics (Nasdaq: NKTR) has announced that it will release its financial results for the second quarter of 2024 on August 8, 2024. The results will be disclosed after the closure of U.S. financial markets, followed by a conference call hosted by CEO Howard Robin at 5:00 p.m. Eastern Time. The conference call will include a review of the results and will be accessible via the company's website, with an option for replay available until September 8, 2024.
Read more →NKTRNektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of a poster highlighting new preclinical data on NKTR-0165 at the European...
Nektar Therapeutics presented promising preclinical data for NKTR-0165, a TNFR2 agonist, at EULAR 2024. The data highlights its selective enhancement of Treg cell function, suggesting potential for treating autoimmune diseases. The company is advancing toward first-in-human studies scheduled for early 2025. However, the development faces inherent risks, as outlined in their forward-looking statements.
Read more →NKTR▼ -8.7%on this news
Nektar Management to Present at Upcoming Investor Conferences Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences: Jefferies Healthcare Conference in New York...
Nektar Therapeutics (Nasdaq: NKTR) management is set to present at various upcoming investor conferences, including the Jefferies Healthcare Conference in New York. The presentations will be accessible via webcast, allowing stakeholders to engage with the company's updates. The webcasts will remain available for replay until early July, ensuring that investors have access to important information regarding the company.
Read more →NKTRNektar Therapeutics Reports First Quarter 2024 Financial Results
Nektar Therapeutics has announced its financial results for the first quarter of 2024, revealing a net loss of $36.8 million. The company reported steady cash and investments, totaling approximately $326 million, which it expects will support operations into mid-2026. Nektar is advancing its pipeline with drug candidates in immunology, notably REZPEG in Phase 2b studies for atopic dermatitis and alopecia areata. Additionally, a novel bivalent antibody targeting TNFR2 receptor is progressing through IND-enabling studies, expected to enter the clinic next year.
Read more →NKTRNektar Therapeutics Reports First Quarter 2024 Financial Results Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024. Cash and investments in marketable...
Nektar Therapeutics reported its financial results for Q1 2024, showing stable revenue of $21.6 million. The company has sufficient cash reserves to fund operations until 2026 and is making progress in its clinical pipeline, particularly with rezpegaldesleukin. However, it reported a net loss of $36.8 million, reflecting ongoing financial challenges.
Read more →NKTRNektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of...
Nektar Therapeutics is scheduled to announce its financial results for the first quarter of 2024 on May 9, 2024, following the close of U.S. financial markets. The announcement will be followed by a conference call hosted by Howard Robin, the company's President and CEO, at 5:00 p.m. Eastern Time. Participants must pre-register to access the live call, which will also be available for replays until June 9, 2024.
Read more →NKTRNektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease...
Nektar Therapeutics management is scheduled to present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 28, 2024. The presentation will include a Q&A session accessible via a webcast, which can be replayed until April 28, 2024. This engagement is part of Nektar's efforts to inform and connect with investors regarding its developments in autoimmune and inflammatory diseases.
Read more →NKTRNektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced the...
Nektar Therapeutics has launched a Phase 2b clinical trial for rezpegaldesleukin (REZPEG), targeting patients with severe to very severe alopecia areata. This study aims to evaluate the efficacy and safety of REZPEG over a 36-week treatment period. The trial will compare different dosing regimens against a placebo in 84 participants, with topline results expected in the first half of 2025. The drug is designed to address underlying immune dysfunction and may offer a new treatment pathway for patients with this condition.
Read more →NKTR▲ +15.4%on this newsshared move
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2023. Cash and...
Nektar Therapeutics reported its financial results for Q4 and the full year 2023, revealing a net loss of $276.1 million. The company has $329.4 million in cash and investments, expected to support operations into 2026. Nektar is advancing its immunology pipeline, with promising data readouts anticipated for REZPEG in 2025. However, the company faced a decrease in revenue and significant impairment charges during the year.
Read more →NKTR▲ +15.4%on this newsshared move
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced that it...
Nektar Therapeutics announced it has signed a securities purchase agreement to undertake a $30 million private placement financing with TCGX. The deal involves the sale of 25 million shares of common stock at $1.20 per share, expected to close by March 6, 2024. This financing is aimed at bolstering the company's financial stability as it progresses with its Phase 2b studies for rezpegaldesleukin, anticipated to yield crucial topline data in the first half of 2025.
Read more →NKTR▲ +15.4%on this newsshared move
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
Nektar Therapeutics reported its financial results for the fourth quarter and full year of 2023, showing a net loss of $276.1 million for the year, though this was an improvement from $368.2 million in 2022. The company highlighted strategic developments in its immunology pipeline, notably for REZPEG and NKTR-0165, with upcoming data readouts anticipated in the next year. Operating costs have decreased significantly compared to 2022, helping to strengthen the company's future operational outlook despite facing ongoing financial losses and impairment charges.
Read more →NKTR▲ +11.9%on this news
Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44th Annual Health Care Conference in Boston on...
Nektar Therapeutics is set to present at the TD Cowen 44th Annual Health Care Conference in Boston on March 5, 2024. The event will begin at 2:10 p.m. Eastern Time and will include a Q&A session accessible via webcast. This presentation highlights Nektar's ongoing commitment to engaging with investors and providing updates on its development programs.
Read more →NKTRNektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2023 on Monday, March 4,...
Nektar Therapeutics will release its financial results for the fourth quarter and the whole year of 2023 on March 4, 2024, after U.S. market close. CEO Howard Robin will host a conference call at 5:00 p.m. Eastern Time to discuss these results. Investors can pre-register for the call to receive dial-in information. The company's R&D pipeline includes investigational medicines in immunology and oncology.
Read more →NKTR▼ -6.4%on this news
Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA Nektar (Nasdaq: NKTR) management is scheduled to present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, ...
Nektar Therapeutics is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 10, 2024. The management's presentation will take place at 5:15 p.m. Pacific Time and will include a Q&A session. Investors and interested parties can access the presentation via a webcast that will be available for replay until February 9, 2024. Nektar is known for its extensive R&D pipeline focused on oncology and immunology.
Read more →NKTRNektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting Nektar Therapeutics (NASDAQ:NKTR) announced that collaborators from the Cairo Laboratory at New York Medical College presented a poster highlighting...
Nektar Therapeutics announced new preclinical data at the 65th ASH Annual Meeting, demonstrating that NKTR-255 can enhance the efficacy of expanded Natural Killer (NK) cells in combination with obinutuzumab against rituximab-resistant Burkitt lymphoma. The data suggests that this combination significantly improves cytotoxicity and survival in relevant mouse models. Nektar's ongoing clinical studies evaluate NKTR-255 in combination therapies for various hematological malignancies, positioning it as a potentially valuable therapeutic option in oncology.
Read more →NKTRNektar Therapeutics Reports Third Quarter 2023 Financial Results
Nektar Therapeutics has announced its financial results for the third quarter of 2023, revealing a loss of $45.8 million. Despite this loss, the company highlighted progress in its pipeline, including upcoming Phase 2b studies for atopic dermatitis and alopecia areata. Nektar also reported a strategic collaboration with Cellular Biomedicine Group for NKTR-255. However, the revenue reported for the first nine months of 2023 fell compared to the same period in the previous year.
Read more →NKTRNektar Therapeutics Reports Third Quarter 2023 Financial Results Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2023. Cash and investments in...
Nektar Therapeutics reported its third-quarter financial results, showing a cash position of $372.7 million. The company is advancing its clinical pipeline with a Phase 2b study for atopic dermatitis and a collaboration for NKTR-255 in lung cancer. However, it also reported a net loss of $45.8 million, reflecting ongoing financial challenges.
Read more →NKTRNektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2023 on Tuesday, November 7, 2023, after the close of...
Nektar Therapeutics (Nasdaq: NKTR) is set to announce its financial results for the third quarter of 2023 on November 7, 2023, after U.S. financial markets close. CEO Howard Robin will lead a conference call at 5:00 p.m. Eastern Time to discuss the results. A link for the conference call and its live audio webcast will be available on Nektar's website, with a replay option until December 8, 2023.
Read more →NKTRNektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress Nektar Therapeutics (NASDAQ:NKTR) today announced new data for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg)...
Nektar Therapeutics has presented promising new data for rezpegaldesleukin (REZPEG) at the 2023 EADV Congress, demonstrating significant efficacy in patients with moderate-to-severe atopic dermatitis. The Phase 1b study results show dose-dependent improvements across multiple clinical endpoints, sustained for 36 weeks after a 12-week treatment period. Furthermore, REZPEG was well tolerated with no severe adverse events. Based on these findings, Nektar plans to initiate two Phase 2 studies targeting atopic dermatitis and alopecia areata.
Read more →NKTRNektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy Nektar Therapeutics (NASDAQ:NKTR) announced today that it will have two presentations for rezpegaldesleukin (REZPEG), a first-in-class selective...
Nektar Therapeutics has announced that two abstracts for its first-in-class selective regulatory T-cell therapy, rezpegaldesleukin (REZPEG), have been accepted for presentation at the EADV Congress 2023. The data includes late-breaking results from a Phase 1b study as well as the design of a forthcoming Phase 2b trial targeting moderate to severe atopic dermatitis. This event is significant as it highlights the potential of REZPEG in treating autoimmune and inflammatory conditions, particularly atopic dermatitis.
Read more →NKTRNektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer Nektar Therapeutics (Nasdaq: NKTR) announced today that it has entered into a new clinical study collaboration with Cellular Biomedicine Group Inc....
Nektar Therapeutics has announced a collaboration with Cellular Biomedicine Group Inc. to conduct a clinical study evaluating NKTR-255 alongside CBMG's C-TIL051 in patients with advanced non-small cell lung cancer (NSCLC) who are resistant to anti-PD-1 therapy. The study, which will take place at Duke Cancer Institute, aims to enhance treatment efficacy using NKTR-255, an IL-15 receptor agonist. The initiative underscores Nektar's focus on innovative cancer therapies and aims to provide significant treatment options for difficult-to-treat NSCLC patients.
Read more →NKTRNektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis Nektar Therapeutics (Nasdaq: NKTR) today announced new data for rezpegaldesleukin in patients with atopic dermatitis, including new clinical efficacy ...
Nektar Therapeutics has reported new, statistically significant efficacy data for rezpegaldesleukin from its Phase 1b study in moderate-to-severe atopic dermatitis. The data indicate a promising improvement in key clinical endpoints, including measures of skin area affected and quality of life. The company is also preparing to initiate a Phase 2a study for alopecia areata in early 2024, signaling a commitment to further research. Investors can expect a detailed presentation of these findings at an upcoming investor and analyst event.
Read more →NKTRNektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event on Wednesday, September 13, 2023 at 11:00 a....
Nektar Therapeutics has announced a virtual investor and analyst event scheduled for September 13, 2023, to present final Phase 1b data for its investigational therapy REZPEG in patients with atopic dermatitis. The event will feature key presentations by Nektar executives and leading dermatology experts. This session aims to inform investors about the treatment landscape and the potential role of REZPEG in addressing moderate to severe atopic dermatitis. Forward-looking statements denote inherent risks and uncertainties related to the drug's clinical development and regulatory approval processes.
Read more →NKTRNektar Therapeutics Reports Second Quarter 2023 Financial Results
Nektar Therapeutics reported its financial results for the second quarter of 2023, showing a net loss of $51.1 million, improved from the previous year's loss. The company's cash positions stand at $409.4 million, expected to sustain operations until mid-2026. Significant decreases in operating expenses, particularly in R&D and G&A, were highlighted, although revenue also experienced a decline. Management announced plans to initiate a Phase 2b study for rezpegaldesleukin and continue developing their pipeline candidates.
Read more →NKTRNektar Therapeutics Reports Second Quarter 2023 Financial Results Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2023. Cash and investments in marketable...
Nektar Therapeutics reported its financial results for Q2 2023, revealing a net loss of $51.1 million, a decrease from $159.1 million in Q2 2022. The company has cash reserves of $409.4 million, expected to last until mid-2026. Nektar is advancing its clinical pipeline, including a Phase 2b study for rezpegaldesleukin and ongoing studies for NKTR-255. Cost reduction measures are also in place to improve financial stability.
Read more →NKTR▲ +91.5%on this newsshared move
Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company Nektar Therapeutics (Nasdaq: NKTR) today announced that efficacy data previously generated by Eli Lilly & Company for rezpegaldesleukin (REZPEG) that ...
Nektar Therapeutics announced that efficacy data for rezpegaldesleukin (REZPEG), previously reported by Eli Lilly, had been incorrectly calculated. The corrected data demonstrate a significant improvement in Eczema Area and Severity Index scores, suggesting that REZPEG may effectively treat atopic dermatitis. Nektar plans to initiate a Phase 2b study of REZPEG for biologic-naïve patients by October 2023, following the analysis of the accurate efficacy data. The discovery of the miscalculations raises questions about the reliability of the initial data reports.
Read more →NKTRNektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2023 on Tuesday, August 8, 2023, after the close of U.S....
Nektar Therapeutics is scheduled to announce its financial results for the second quarter of 2023 on August 8, 2023, after U.S. markets close. The announcement will be accompanied by a conference call led by President and CEO Howard Robin, starting at 5:00 p.m. Eastern Time. Investors can access the call via a pre-registration link provided on the company's website, where a replay will also be available for a limited time. Nektar Therapeutics continues to develop investigational medicines in immunology and oncology.
Read more →NKTRNektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 44th...
Nektar Therapeutics will participate in a virtual fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on June 14, 2023. Senior management from Nektar is scheduled to present at 1:20 p.m. Pacific Time, with the presentation available via webcast. The event will showcase Nektar's investigational medicines in immunology and oncology, emphasizing the company's strong R&D pipeline.
Read more →NKTRNektar Therapeutics Reports First Quarter 2023 Financial Results
Nektar Therapeutics reported its first quarter 2023 financial results, revealing a net loss of $137 million compared to $90.4 million in the same quarter of 2022. The company's cash and marketable securities decreased but are expected to support operations into 2026. Nektar is focused on advancing its immunology pipeline, particularly with the drug rezpegaldesleukin for atopic dermatitis. Overall operating costs have significantly increased, necessitating careful financial management.
Read more →NKTRNektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development Company plans to move REZPEG fo
Nektar Therapeutics has regained full rights to its investigational therapy, Rezpegaldesleukin (REZPEG), from Eli Lilly and Company. The company plans to move forward with a Phase 2b clinical study in patients with moderate-to-severe atopic dermatitis, following promising Phase 1b data that reflected dose-dependent improvements in key efficacy measures. The therapy is intended to stimulate regulatory T-cells to address immune system imbalances. Nektar views REZPEG as a potential innovative treatment that could bring long-term disease control to atopic dermatitis patients.
Read more →NKTR▲ +6.3%on this news
Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan -- Pipeline focus will prioritize programs in immunology, including REZPEG and several immunology research programs -- -- Development o
Nektar Therapeutics has announced a strategic reprioritization and cost restructuring plan aimed at focusing its pipeline on immunology products, including REZPEG. The company will reduce its workforce by about 60%, which is expected to significantly lower operating expenses and extend its cash runway into mid-2026, with an estimated annual savings of $30 million. The development of NKTR-255 in blood cancers will continue as the company explores strategic partnerships. Financial results for the first quarter of 2023 are set to be announced on May 9, 2023.
Read more →NKTRNektar Therapeutics Issues Statement Confirming That It Does Not Hold Any Cash Deposits or Securities at Silicon Valley Bank
Nektar Therapeutics has confirmed that it does not hold any cash deposits or securities at Silicon Valley Bank, following recent banking concerns. As of December 31, 2022, the company reported approximately $505 million in cash and investments. This statement reassures stakeholders about Nektar's financial stability and independence from the troubled bank. The company continues to focus on its robust research and development pipeline in oncology and immunology.
Read more →NKTRNektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results
Nektar Therapeutics reported its financial results for the fourth quarter and full year of 2022, revealing a decline in revenue from the previous year. While the company holds $505 million in cash, it is taking steps to reduce operating costs due to decreasing revenues and increased net losses. The wind down of the bempegaldesleukin program has led to significant restructuring costs. Despite these challenges, Nektar announced topline data from a Phase 2 study of rezpegaldesleukin.
Read more →NKTRNektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus Nektar Therapeutics (Nasdaq: NKTR) today announced topline data from a Phase 2 randomized, double-blind, placebo-controlled study of...
Nektar Therapeutics announced topline data from a Phase 2 study of Rezpegaldesleukin (REZPEG) in patients with systemic lupus erythematosus (SLE). The study showed improvement in secondary endpoints, although the primary endpoint was not achieved. There are plans for further trials in other indications, particularly atopic dermatitis, following discussions with its partner, Lilly. Despite mixed results, the study indicated potential efficacy in regulating T cells for treating autoimmune diseases.
Read more →NKTRPhase 2 ISLAND Study of REZPEG in SLE Topline Data Results
Nektar has presented the topline data results from the Phase 2 ISLAND study of its investigational drug REZPEG for systemic lupus erythematosus (SLE). The study assessed several endpoints, primarily focusing on the SLEDAI index but encountered limitations as the primary endpoint was not deemed critical for success. Notably, the study results indicated that it did not reach statistical power for its secondary endpoints, raising concerns about the efficacy of REZPEG compared to established treatments. This data could influence future decisions on advancement to Phase 3 trials.
Read more →NKTR▲ +6.8%on this news
Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 41st Annual J.P....
Nektar Therapeutics' President and CEO Howard Robin is set to present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023. The event will feature a presentation and Q&A session accessible via webcast, which will remain available for replay until February 11, 2023. Nektar has a robust R&D pipeline in oncology and immunology, signaling its ongoing commitment to drug development and innovation in the biopharmaceutical sector.
Read more →NKTRNektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) today announced two presentations of NKTR-255 at the 64th American Society of Hematology (ASH) Annual Meeting....
-- Unveils Trial Design for Nektar Phase 2/3 Study Combining NKTR-255 with CAR-T Therapies -- -- Presents First Data for NKTR-255 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma -- SAN FRANCISCO , Dec. 12, 2022 /PRNewswire/ -- Nektar Therap
Read more →NKTRNektar Therapeutics to Host Investor & Analyst Event on December 12th Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host an investor and analyst event on Monday, December 12, 2022 at 7:30 a.m. CST....
SAN FRANCISCO , Dec. 5, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that it will host an investor and analyst event on Monday, December 12, 2022 at 7:30 a.m. CST . Nektar management will be joined by Dr. Cameron Turtle , Professor and Chair of Cancer
Read more →NKTR▲ +8.7%on this news· ran to +20% by day 1
Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) today announced the first presentation of preclinical data for NKTR-288 at the 2022 Society for Immunotherapy of...
NKTR-288 upregulated MHC Class I and PD-L1 expression on tumors, enhancing anti-tumor activity when combined with anti-PD-1 or anti-PD-L1 antibodies SAN FRANCISCO , Nov. 10, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced the first presentation of precli
Read more →NKTR▼ -5.5%on this newsshared move
Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in Blood Advances, the open-access journal of the American...
-- Polymer-conjugated IL-15 (NKTR-255) induced CD8 + T cell and natural killer cell proliferation in vivo -- -- NKTR-255 enhanced the efficacy of human CD19 CAR-T cells in a xenogeneic lymphoma model -- SAN FRANCISCO , Nov. 9, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: N
Read more →NKTRNektar Therapeutics Reports Third Quarter 2022 Financial Results
Reports Third Quarter 2022 Financial Results SAN FRANCISCO, Nov. 3, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2022. Cash and investments in marketable securities on September 30, 2022, we
Read more →NKTRNektar to Announce Financial Results for the Third Quarter 2022 on Thursday, November 3, 2022, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2022 on Thursday, November 3, 2022, after the close of U....
SAN FRANCISCO , Oct. 25, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the third quarter 2022 on Thursday, November 3, 2022 , after the close of U.S.-based financial markets. Howard Robin , President and Chief Executive Officer,
Read more →NKTRNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS AND MERGERS
Read more →NKTRNektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (EADV) Congress Nektar Therapeutics (Nasdaq: NKTR) today announced data presentations from two Phase 1b, proof-of-concept studies of rezpegaldesleukin (also known as ...
SAN FRANCISCO , Sept. 7, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced data presentations from two Phase 1b , proof-of-concept studies of rezpegaldesleukin (also known as LY3471851 or NKTR-358) in patients with atopic dermatitis (AD) and plaque psoriasi
Read more →NKTRNektar and Collaborators Announce Preclinical Publication of Data for NKTR-255 and its Observed Improvement of NK Cell Function in Multiple Myeloma Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in Blood Advances, the open-access journal of the American...
SAN FRANCISCO , Aug. 16, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced the publication of preclinical data in Blood Advances , the open-access journal of the American Society of Hematology, highlighting the effects of NKTR-255, a novel polymer-conjugate
Read more →NKTRNektar Therapeutics Reports Second Quarter 2022 Financial Results
Reports Second Quarter 2022 Financial Results SAN FRANCISCO, August 4, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June Cash and investments in marketable securities at June 30, 2022, were approximately
Read more →NKTR▲ +5.9%on this news
Nektar to Announce Financial Results for the Second Quarter 2022 on Thursday, August 4, 2022, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2022 on Thursday, August 4, 2022, after the close of...
SAN FRANCISCO , July 26, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the second quarter 2022 on Thursday, August 4, 2022 , after the close of U.S.-based financial markets. Howard Robin , President and Chief Executive Officer, w
Read more →NKTRNektar Announces Promotion of Jillian B. Thomsen to Senior Vice President & Chief Financial Officer Nektar Therapeutics (Nasdaq: NKTR) today announced the promotion of Jillian B. Thomsen to Senior Vice President (SVP) & Chief Financial Officer. Ms....
SAN FRANCISCO , July 1, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced the promotion of Jillian B. Thomsen to Senior Vice President (SVP) & Chief Financial Officer. Ms. Thomsen has served as SVP, Finance & Chief Accounting Officer of Nektar since 2008, a
Read more →NKTRNektar Therapeutics Reports First Quarter 2022 Financial Results
Reports First Quarter 2022 Financial Results 5, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March Cash and investments in marketable securities at March 31, 2022 were approximately $704.4 million as compa
Read more →NKTRNektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook Company focusing on key pipeline programs NKTR-358, NKTR-255 and core research programs Cost restructuring plan results in cash runway int
Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook Company focusing on key pipeline programs NKTR-358, NKTR-255 and core research programs Cost restructuring plan results in cash runway into the first half of 2025 Analyst and investor conferen
Read more →NKTRNektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® Nektar Therapeutics (Nasdaq: NKTR) announced that collaborators from the Cairo Laboratory at New York Medical College today presented data from...
SAN FRANCISCO , April 23, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced that collaborators from the Cairo Laboratory at New York Medical College today presented data from several preclinical studies demonstrating the potential of NKTR-255 to enhance the anti-
Read more →NKTRNektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline New Strategic Plan Nektar Therapeutics (NASDAQ:NKTR) will host an analyst and investor conference call with Nektar executives on Monday, April 25, 2022, at 2:00 p.m....
SAN FRANCISCO , April 22, 2022 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) will host an analyst and investor conference call with Nektar executives on Monday, April 25, 2022 , at 2:00 p.m. Pacific Standard Time (PST), to outline a new strategic plan for the company and pr
Read more →NKTRNektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) (PRINCETON, N.J., &
Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) (PRINCETON, N.J., & SAN FRANCISCO, April 14, 2022) -- Nektar Therapeutics (NASDAQ: NKTR) and Bristol Myers Squibb (NYSE: BMY) t
Read more →NKTR▼ -60.9%on this news
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors Following Announcement of Update from Bristol-Myers Squibb and Nektar on the PIVOT-IO-001 Phase 3 Trial Nektar Therapeutics (NASDAQ:NKTR) will hold an analyst and investor conference call with Nektar management today, Monday, March 14, 2022, at 5:00 a.m....
SAN FRANCISCO , March 14, 2022 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) will hold an analyst and investor conference call with Nektar management today, Monday, March 14, 2022 , at 5:00 a.m. Pacific Standard Time (PST), following this morning's update from Bristol-Myers
Read more →NKTR▼ -60.9%on this news
Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma (PRIN
Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma (PRINCETON, N.J., & SAN FRANCISCO, March 14, 2022) -- Bristol
Read more →NKTRNektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results
Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results SAN FRANCISCO, Feb. 28, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2021. Cash and investments i
Read more →NKTRNektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2021 on Monday, February 28, 2022, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2021 on Monday, February...
SAN FRANCISCO , Feb. 17, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the fourth quarter and year-ended December 31, 2021 on Monday, February 28, 2022, after the close of U.S.-based financial markets. Howard Robin, President and
Read more →NKTR▼ -6.9%on this news
Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 40th Annual J.P....
SAN FRANCISCO , Jan. 5, 2022 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) President and Chief Executive Officer, Howard Robin , is scheduled to present at the upcoming 40th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, January 11, 2022 at 3:00 p.m. Eastern
Read more →NKTRNektar Therapeutics Announces Phase 1b Data for Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Atopic Dermatitis Nektar Therapeutics (NASDAQ: NKTR) today announced that its partner Eli Lilly & Company presented preliminary results from a Lilly-sponsored Phase 1b ...
SAN FRANCISCO , Dec. 15, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced that its partner Eli Lilly & Company presented preliminary results from a Lilly-sponsored Phase 1b proof-of-concept study of NKTR-358 (LY3471851 * ), a novel T regulatory (Treg) cell
Read more →NKTRNektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, at the 63rd American Society of Hematology (ASH) Annual Meeting Nektar Therapeutics (NASDAQ:NKTR) announced two data presentations from the dose-escalation portion of its ongoing Phase 1 study of NKTR-255 in...
SAN FRANCISCO , Dec. 13, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced two data presentations from the dose-escalation portion of its ongoing Phase 1 study of NKTR-255 in patients with relapsed/refractory hematologic malignancies at the 63 rd American Society
Read more →NKTRNektar Therapeutics Announces Data Presentations for its Immuno-Oncology Programs at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021 and the 63rd American Society of Hematology (ASH) Annual Meeting Nektar Therapeutics (NASDAQ: NKTR) announced today that it will present data at two upcoming medical meetings for two of its cytokine immuno-oncology ...
SAN FRANCISCO , Nov. 30, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today that it will present data at two upcoming medical meetings for two of its cytokine immuno-oncology programs: IL-2 agonist, bempegaldesleukin (BEMPEG), and IL-15 agonist, NKTR-255. Th
Read more →NKTRNektar Therapeutics Strengthens Board of Directors with Appointment of Diana M. Brainard, M.D. Nektar Therapeutics (NASDAQ: NKTR) today announced it has appointed Diana M. Brainard, M.D., as an independent director to its Board of Directors. Dr....
SAN FRANCISCO , Nov. 15, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced it has appointed Diana M. Brainard , M.D., as an independent director to its Board of Directors. Dr. Brainard brings over two decades of experience working in the healthcare sector a
Read more →NKTRNektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) today announced three data presentations for its I-O pipeline at the 2021 Society for Immunotherapy of Cancer...
SAN FRANCISCO , Nov. 12, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced three data presentations for its I-O pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting. Initial clinical results were presented from the dose-escalation
Read more →NKTR▼ -5.7%on this newsshared move
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Cancer Specialist During 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting Nektar Therapeutics (NASDAQ:NKTR) announced today that it will host a webcast analyst and investor conference call with a cancer specialist and...
SAN FRANCISCO , Nov. 9, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today that it will host a webcast analyst and investor conference call with a cancer specialist and Nektar management on Friday, November 12, 2021 , at 12:00 p.m. EST during the 2021 Societ
Read more →NKTRNektar Therapeutics Reports Third Quarter 2021 Financial Results
Nektar Therapeutics Reports Third Quarter 2021 SAN FRANCISCO, November 4, 2021 -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2021. Cash and investments in marketable securities at September 30, 2021 were appro
Read more →NKTRNektar to Announce Financial Results for the Third Quarter 2021 on Thursday, November 4, 2021, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2021 on Thursday, November 4, 2021, after the close of U....
SAN FRANCISCO , Oct. 26, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the third quarter 2021 on Thursday, November 4, 2021, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, wi
Read more →NKTR▲ +8.4%on this news
Nektar Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germany and Pfizer Inc. to Combine NKTR-255, a Novel Interleukin-15 Agonist, with Avelumab in the JAVELIN Bladder Medley Study Nektar Therapeutics (NASDAQ: NKTR) announced it has entered into a new oncology clinical collaboration with Merck KGaA, Darmstadt, Germany and Pfizer ...
SAN FRANCISCO , Sept. 21, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced it has entered into a new oncology clinical collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to evaluate the maintenance regimen of NKTR-255, Nektar's interleukin-15 (IL-
Read more →NKTRNektar Therapeutics Reports Second Quarter 2021 Financial Results
Nektar Therapeutics Reports Second Quarter 2021 SAN FRANCISCO, August 5, 2021 -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2021. Cash and investments in marketable securities at June 30, 2021 were approximately $
Read more →NKTRNektar to Announce Financial Results for the Second Quarter 2021 on Thursday, August 5, 2021, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2021 on Thursday, August 5, 2021, after the close of...
SAN FRANCISCO , July 27, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the second quarter 2021 on Thursday, August 5, 2021, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, wil
Read more →NKTRNektar Appoints Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer Nektar Therapeutics (Nasdaq: NKTR) announced today that it has appointed Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical ...
SAN FRANCISCO , July 19, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that it has appointed Dimitry S.A. Nuyten , M.D., Ph.D., as Senior Vice President and Chief Medical Officer (CMO). In his role as CMO, Dr. Nuyten will have oversight for the company'
Read more →NKTRNektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 42nd...
SAN FRANCISCO , June 7, 2021 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 42 nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 2:10 p.m. Eastern Time .
Read more →NKTRNektar Therapeutics Announces First Publication of NKTR-358, a Novel Molecule Designed to Selectively Stimulate Expansion and Selective Function of T Regulatory Cells, in the Journal of Translational Autoimmunity Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in the Journal of Translational Autoimmunity describing...
SAN FRANCISCO , May 20, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced the publication of preclinical data in the Journal of Translational Autoimmunity describing NKTR-358, a first-in-class, composition of stable PEG conjugates of native IL-2 designed to
Read more →NKTRNektar Therapeutics Announces its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC) Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data from its second major immuno-oncology cytokine program,...
SAN FRANCISCO , May 18, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced the publication of preclinical data from its second major immuno-oncology cytokine program, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC) . NKTR-255 is a novel recombina
Read more →NKTRNektar Therapeutics Reports First Quarter 2021 Financial Results
Therapeutics Reports First Quarter 2021 Financial Results FRANCISCO, May 6, 2021 -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2021. and investments in marketable securities at March 31, 2021 were approximately $1.
Read more →NKTRNektar to Announce Financial Results for the First Quarter 2021 on Thursday, May 6, 2021, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2021 on Thursday, May 6, 2021, after the close of...
SAN FRANCISCO , April 27, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the first quarter 2021 on Thursday, May 6, 2021, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will h
Read more →NKTRNektar Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results
Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results FRANCISCO, Feb. 25, 2021/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2020. and investments in marketable secur
Read more →NKTRNektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2020, on Thursday, February ...
SAN FRANCISCO , Feb. 18, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the fourth quarter and year-ended December 31, 2020 , on Thursday, February 25, 2021, after the close of U.S.-based financial markets. Howard Robin, President
Read more →NKTRNektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) Nektar Therapeutics (NASDAQ: NKTR) announced today that it has entered into a clinical trial collaboration and supply agreement with Merck (known as...
SAN FRANCISCO , Feb. 17, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada ) for a Phase 2/3 study of bempegaldesleuki
Read more →NKTRNektar Announces Collaboration with SFJ Pharmaceuticals® for Bempegaldesleukin in Head and Neck Cancer Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies...
SAN FRANCISCO , Feb. 17, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cancer and auto-immune disease, today announced a financing and co-development col
Read more →NKTRNektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 39th Annual J.P....
SAN FRANCISCO , Jan. 6, 2021 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) President and Chief Executive Officer, Howard Robin , is scheduled to present at the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021 at 11:50 a.m. Pacific
Read more →NKTRNektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer and Head of Development Nektar Therapeutics (NASDAQ: NKTR) announced today that it has appointed Brian Kotzin, MD as Interim Chief Medical Officer, Head of Development...
SAN FRANCISCO , Jan. 5, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today that it has appointed Brian Kotzin , MD as Interim Chief Medical Officer, Head of Development effective immediately. Since 2017, Dr. Kotzin has served as Senior Vice President, Clinic
Read more →NKTRNektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE® and MOVANTIK® Royalties for $150 Million Nektar Therapeutics (NASDAQ: NKTR) today announced that it agreed to sell to entities managed by Healthcare Royalty Management, LLC (HCR) its...
SAN FRANCISCO , Dec. 22, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced that it agreed to sell to entities managed by Healthcare Royalty Management, LLC (HCR) its royalties on future sales of ADYNOVATE, under Nektar's agreement with Baxalta Incorporated,
Read more →NKTRNektar Therapeutics Announces Dosing of First Patients in Phase 1/2 Study of its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma or Colorectal Cancer Nektar Therapeutics (NASDAQ:NKTR) today announced that the first patient has been dosed in the Phase 1/2 trial of NKTR-255, Nektar's investigational...
SAN FRANCISCO , Dec. 15, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced that the first patient has been dosed in the Phase 1/2 trial of NKTR-255, Nektar's investigational IL-15 pathway agonist, in patients with relapsed or refractory (R/R) head and neck
Read more →NKTRNektar Therapeutics Announces Presentation of Preclinical Data for NKTR-255, its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual Meeting Nektar Therapeutics (NASDAQ: NKTR) today announced two nonclinical data presentations for NKTR-255, its IL-15 pathway agonist, at the 62nd American...
SAN FRANCISCO , Dec. 7, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced two nonclinical data presentations for NKTR-255, its IL-15 pathway agonist, at the 62 nd American Society of Hematology (ASH) Annual Meeting. The presentations include an oral present
Read more →NKTRNektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) today announced four data presentations for its I-O pipeline from three separate clinical-stage investigational...
SAN FRANCISCO , Nov. 11, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced four data presentations for its I-O pipeline from three separate clinical-stage investigational agents at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting. New cli
Read more →NKTRNektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Expert Oncologist Panel During 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting Nektar Therapeutics (NASDAQ:NKTR) announced today that it will host a webcast analyst and investor conference call with a panel of oncology experts...
SAN FRANCISCO , Nov. 9, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today that it will host a webcast analyst and investor conference call with a panel of oncology experts and company management on Wednesday, November 11, 2020 , at 4:15 p.m. EST during the
Read more →NKTRNektar Therapeutics Reports Third Quarter 2020 Financial Results
Nektar Therapeutics Reports Third Quarter 2020 Financial Results SAN FRANCISCO, November 5, 2020 -- Nektar Therapeutics (NASDAQ: NKTR) today reported financial results for the third quarter ended September 30, 2020. Cash and investments in marketable securities at September 3
Read more →NKTRNew Clinical Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at 2020 American College of Rheumatology (ACR) Congress Nektar Therapeutics (NASDAQ:NKTR) announced the presentation of additional clinical data from the Phase 1b study evaluating multiple ascending doses...
SAN FRANCISCO , Nov. 4, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced the presentation of additional clinical data from the Phase 1b study evaluating multiple ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator, currently in development
Read more →NKTRNektar Therapeutics to Host Webcast Conference Call for Analysts & Investors for 2020 American College of Rheumatology (ACR) Congress Nektar Therapeutics (NASDAQ: NKTR) announced today that it will webcast an analyst and investor conference call at ACR 2020 with company management...
SAN FRANCISCO , Oct. 29, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today that it will webcast an analyst and investor conference call at ACR 2020 with company management and Dr. Klatzmann of Sorbonne University on Wednesday, November 4, 2020 at 4:15 p.m.
Read more →NKTRNektar to Announce Financial Results for the Third Quarter 2020 on Thursday, November 5, 2020, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2020 on Thursday, November 5, 2020, after the close of U....
SAN FRANCISCO , Oct. 28, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the third quarter 2020 on Thursday, November 5, 2020 , after the close of U.S.-based financial markets. Howard Robin , President and Chief Executive Officer,
Read more →NKTRNektar Therapeutics Announces Phase 1b Clinical Study to Evaluate Bempegaldesleukin for Treatment of Patients Diagnosed with Mild COVID-19 Nektar Therapeutics (NASDAQ: NKTR) today announced that it has received FDA clearance for an Investigational New Drug (IND) application for its...
SAN FRANCISCO , Oct. 27, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced that it has received FDA clearance for an Investigational New Drug (IND) application for its investigational IL-2 pathway agent, bempegaldesleukin (BEMPEG, NKTR-214), to be evaluated
Read more →NKTRVaccibody AS and Nektar Therapeutics Announce First Patient Dosed in a Phase 1/2a Study Arm Evaluating VB10.NEO, a Personalized Neoantigen Cancer Vaccine, with Bempegaldesleukin (NKTR-214) in Patients with Squamous Cell Carcinoma of the Head and Neck Vaccibody AS and Nektar Therapeutics (NASDAQ: NKTR) today announced that the first patient has been dosed in the combination therapy of the Phase...
OSLO, Norway and SAN FRANCISCO , Aug. 12, 2020 /PRNewswire/ -- Vaccibody AS and Nektar Therapeutics (NASDAQ: NKTR ) today announced that the first patient has been dosed in the combination therapy of the Phase 1/2a study evaluating bempegaldesleukin (bempeg), Nektar's CD122-prefe
Read more →NKTRNektar Therapeutics Reports Second Quarter 2020 Financial Results
Nektar Therapeutics Reports Second Quarter 2020 Financial Results SAN FRANCISCO, August 6, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2020. Cash and investments in marketable securities at Ju
Read more →NKTRNektar to Announce Financial Results for the Second Quarter 2020 on Thursday, August 6, 2020, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2020 on Thursday, August 6, 2020, after the close of...
SAN FRANCISCO , July 28, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the second quarter 2020 on Thursday, August 6, 2020 , after the close of U.S.-based financial markets. Howard Robin , President and Chief Executive Officer, w
Read more →NKTRData Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020) Nektar Therapeutics (NASDAQ:NKTR) today announced the presentation of results from the Phase 1b study evaluating multiple ascending doses of...
SAN FRANCISCO , June 4, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced the presentation of results from the Phase 1b study evaluating multiple ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator, which is being developed as a poten
Read more →NKTRNektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020) Nektar Therapeutics (NASDAQ: NKTR) announced today that it will webcast an analyst and investor conference call on Friday, June 5, 2020 at 11:00 a.m. ...
SAN FRANCISCO , May 29, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today that it will webcast an analyst and investor conference call on Friday, June 5, 2020 at 11:00 a.m. EDT during EULAR 2020. The event will follow Thursday's virtual poster presentation
Read more →NKTRNektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of Phase 1 clinical data for its lead immuno-oncology candidate, bempegaldesleukin ...
SAN FRANCISCO , May 22, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced the publication of Phase 1 clinical data for its lead immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) in combination with nivolumab, in Cancer Discovery, a journal of
Read more →NKTRNektar Therapeutics Reports First Quarter 2020 Financial Results
Nektar Therapeutics Reports First Quarter 2020 Financial Results SAN FRANCISCO, May 7, 2020 - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2020. Cash and investments in marketable securities at March 31, 2020 were
Read more →NKTRNektar to Announce Financial Results for the First Quarter 2020 on Thursday, May 7, 2020, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2020 on Thursday, May 7, 2020, after the close of...
SAN FRANCISCO , April 28, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the first quarter 2020 on Thursday, May 7, 2020 , after the close of U.S.-based financial markets. Howard Robin , President and Chief Executive Officer, will
Read more →NKTRA Letter from our President & CEO, Howard Robin (updated
A Letter from our President & CEO, Howard Robin (updated April 1, 2020) This is an unprecedented time. Nektar and our partners are navigating a complex situation of new and rapidly evolving information and guidelines. The safety and well-being of our fellow employees, and the
Read more →NKTRNektar Therapeutics to Webcast Presentation at the Cowen and Company 40th Annual Health Care Conference Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to present at the upcoming Cowen and Company 40th Annual Health Care Conference in ...
SAN FRANCISCO , Feb. 28, 2020 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) senior management is scheduled to present at the upcoming Cowen and Company 40th Annual Health Care Conference in Boston on Tuesday, March 3, 2020 at 9:20 a.m. Eastern Time . The presentation will
Read more →NKTRNektar Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results
Nektar Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results SAN FRANCISCO, February 27, 2020 - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2019. Cash and investments in marketab
Read more →NKTRNektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2019 on Thursday, February 27, 2020, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2019, on Thursday, February ...
SAN FRANCISCO , Feb. 18, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the fourth quarter and year-ended December 31, 2019 , on Thursday, February 27, 2020 , after the close of U.S.-based financial markets. Howard Robin , Preside
Read more →NKTRNektar Therapeutics Announces Publication of Two Manuscripts on Lead Immuno-oncology Candidate, Bempegaldesleukin (Bempeg) in Nature Communications Nektar Therapeutics (NASDAQ: NKTR) today announced the publication of preclinical data on its lead immuno-oncology candidate, NKTR-214,...
SAN FRANCISCO , Feb. 3, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced the publication of preclinical data on its lead immuno-oncology candidate, NKTR-214 , bempegaldesleukin (bempeg) in two manuscripts in Nature Communications . Bempeg is an investigati
Read more →NKTRNektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol Nektar Therapeutics (NASDAQ: NKTR) issued a statement today following a meeting of the Food and Drug Administration's (FDA's) Anesthetic and...
SAN FRANCISCO , Jan. 14, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) issued a statement today following a meeting of the Food and Drug Administration's (FDA's) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) and Drug Safety and Risk Management Advi
Read more →NKTRNektar Therapeutics' President and CEO, Howard Robin, To Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 38th Annual J.P....
SAN FRANCISCO , Jan. 7, 2020 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) President and Chief Executive Officer, Howard Robin , is scheduled to present at the upcoming 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2020 at 2:30 p.m.
Read more →NKTRNektar Therapeutics Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D. Nektar Therapeutics (NASDAQ: NKTR) today announced it has appointed Myriam J. Curet, M.D., as an independent director to its Board of Directors. Dr....
SAN FRANCISCO , Dec. 17, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced it has appointed Myriam J. Curet , M.D., as an independent director to its Board of Directors. Dr. Curet brings three decades of experience working in the healthcare sector and acade
Read more →NKTRNektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting Nektar Therapeutics (NASDAQ: NKTR) today announced three presentations at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition...
SAN FRANCISCO , Dec. 9, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced three presentations at the 61 st American Society of Hematology (ASH) Annual Meeting & Exposition for its IL-15 agonist and investigational candidate, NKTR-255. Data were presented fr
Read more →NKTRNektar Appoints John Northcott as Chief Commercial Officer Nektar Therapeutics (NASDAQ:NKTR) announced today that John Northcott has joined the company in the newly-created position of Senior Vice President...
SAN FRANCISCO , Dec. 3, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today that John Northcott has joined the company in the newly-created position of Senior Vice President and Chief Commercial Officer. John will also serve as a member of the Company's Execu
Read more →NKTRNektar to Webcast Presentation at Jefferies 2019 London Healthcare Conference Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to present at the upcoming Jefferies 2019 Healthcare Conference in London on...
SAN FRANCISCO , Nov. 13, 2019 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) senior management is scheduled to present at the upcoming Jefferies 2019 Healthcare Conference in London on Wednesday, November 20, 2019 at 4:00 p.m. Greenwich Mean Time. The presentation will be
Read more →NKTRNektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology Nektar Therapeutics (NASDAQ: NKTR) today announced updated results from the first-in-human Phase 1a study of NKTR-358, a novel T regulatory (Treg)...
SAN FRANCISCO , Nov. 10, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced updated results from the first-in-human Phase 1a study of NKTR-358, a novel T regulatory (Treg) cell stimulator in development for the treatment of autoimmune and other chronic infla
Read more →NKTRNektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of five clinical and preclinical data abstracts focused on its immuno-oncology...
SAN FRANCISCO , Nov. 9, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced the presentation of five clinical and preclinical data abstracts focused on its immuno-oncology portfolio at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting. New c
Read more →NKTRNektar Therapeutics Reports Financial
Nektar Therapeutics Reports Financial for the Third Quarter of 2019 SAN FRANCISCO, November 6, 2019 - Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2019. Cash and investments in marketable securities at Septe
Read more →NKTRNektar Therapeutics Reports Financial Results for the Third Quarter of 2019 Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2019. Cash and investments in...
SAN FRANCISCO , Nov. 6, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial results for the third quarter ended September 30, 2019 . Cash and investments in marketable securities at September 30, 2019 were approximately $1.7 billion as compared
Read more →NKTRNektar Therapeutics to Host Webcast Conference Call with Melanoma Specialist for Analysts & Investors During 2019 Society for Immunotherapy of Cancer 34th Annual Meeting Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with a melanoma specialist and company ...
SAN FRANCISCO , Nov. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today that it will webcast an analyst and investor conference call with a melanoma specialist and company management on Sunday, November 10, 2019 at 9:00 a.m. EST in Washington, D.C. during
Read more →NKTRNektar to Announce Financial Results for the Third Quarter 2019 on Wednesday, November 6, 2019, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Wednesday, November 6, 2019, after the close of...
SAN FRANCISCO , Oct. 30, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the third quarter on Wednesday, November 6, 2019 , after the close of U.S.-based financial markets. Howard Robin , President and Chief Executive Officer, will
Read more →NKTRNektar Therapeutics Announces Initiation of First-in-Human Phase 1 Clinical Study of NKTR-255, an IL-15 Agonist, in Adults with Relapsed or Refractory Non-Hodgkin Lymphoma or Multiple Myeloma Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of a first-in-human, Phase 1 clinical study evaluating NKTR-255, an interleukin-15...
SAN FRANCISCO , Oct. 16, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced the initiation of a first-in-human, Phase 1 clinical study evaluating NKTR-255, an interleukin-15 (IL-15) receptor agonist, as monotherapy for patients with relapsed or refractory no
Read more →NKTRNektar Therapeutics Announces Initiation of Two Clinical Studies of Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Psoriasis and Atopic Dermatitis Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of two Phase 1b studies of NKTR-358 (LY3471851*), a novel T regulatory (Treg) cell...
SAN FRANCISCO , Oct. 7, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced the initiation of two Phase 1b studies of NKTR-358 (LY3471851*), a novel T regulatory (Treg) cell stimulator, one in patients with psoriasis and one in patients with atopic dermatitis
Read more →NKTRNektar Therapeutics Announces Five Abstracts Accepted for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) today announced the acceptance of five clinical and preclinical data abstracts for its immuno-oncology portfolio...
SAN FRANCISCO , Oct. 2, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced the acceptance of five clinical and preclinical data abstracts for its immuno-oncology portfolio at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting. The presentatio
Read more →NKTRNektar Announces Key Executive Promotions Nektar Therapeutics (Nasdaq: NKTR) announced today several promotions on its executive leadership team: Jonathan Zalevsky, Ph.D. has been promoted to ...
SAN FRANCISCO , Oct. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today several promotions on its executive leadership team: "I am very pleased to announce these two well-deserved promotions on Nektar's Executive Committee," said Howard W. Robin , Presid
Read more →NKTRClinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Triple-Negative Breast Cancer Patients at the 2019 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation of new clinical data for bempegaldesleukin (bempeg, NKTR-214) in combination with...
SAN FRANCISCO , Sept. 26, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today a presentation of new clinical data for bempegaldesleukin (bempeg, NKTR-214) in combination with nivolumab in patients with advanced or metastatic triple-negative breast cancer (TNB
Read more →NKTRNektar Therapeutics Announces Abstract Accepted for Presentation at the 5th CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference Nektar Therapeutics (Nasdaq: NKTR) today announced that new data from a cohort of patients with metastatic triple-negative breast cancer who were...
SAN FRANCISCO , Sept. 23, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that new data from a cohort of patients with metastatic triple-negative breast cancer who were enrolled in the PIVOT-02 study will be presented at the upcoming 5th CRI-CIMT-EATI-AAC
Read more →NKTRNektar Therapeutics Reports Financial Results for the Second Quarter of 2019 Company to Host Conference Call with Analysts to Review Financial Results and Provide Update on the NKTR-214 (bempegaldesleukin) Program
Therapeutics Reports Financial Results for the Second Quarter of 2019 Company to Host Conference Call with Analysts to Review Financial Results and Provide Update on the NKTR-214 (bempegaldesleukin) Program SAN FRANCISCO, August 8, 2019 --- Nektar Therapeutics (Nasdaq: NKTR)
Read more →NKTRNektar to Announce Financial Results for the Second Quarter 2019 on Thursday, August 8, 2019, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 8, 2019, after the close of...
SAN FRANCISCO , July 30, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the second quarter on Thursday, August 8, 2019 , after the close of U.S.-based financial markets. Howard Robin , President and Chief Executive Officer, will h
Read more →NKTRFirst-in-Human Data Presented from Phase 1a Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology Nektar Therapeutics (Nasdaq: NKTR) today announced the results of the first-in-human Phase 1a study evaluating single-ascending doses of NKTR-358, a...
MADRID and SAN FRANCISCO , June 13, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced the results of the first-in-human Phase 1a study evaluating single-ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator in clinical development for t
Read more →NKTRNektar Therapeutics to Host Webcast Conference Call with Immunology Expert for Analysts & Investors During 2019 European Congress of Rheumatology (EULAR 2019) Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with an immunology expert and company...
SAN FRANCISCO , June 11, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today that it will webcast an analyst and investor conference call with an immunology expert and company management on Thursday, June 13, 2019 at 8:00 a.m. EDT during EULAR 2019. The event
Read more →NKTRNektar Therapeutics Presents Biomarker and Clinical Data from PIVOT-02 Phase 2 Study of Bempegaldesleukin with Nivolumab at 2019 ASCO Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) announced today that biomarker and clinical data from PIVOT-02 is being presented at the 2019 American Society of...
CHICAGO , June 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that biomarker and clinical data from PIVOT-02 is being presented at the 2019 American Society of Clinical Oncology (ASCO) Meeting in Chicago , Illinois. New baseline biomarker analyses an
Read more →NKTRNektar Announces the Launch of Inheris Biopharma, Inc. Nektar Therapeutics (Nasdaq: NKTR) today announced the formation of Inheris Biopharma, Inc., a wholly-owned subsidiary of Nektar and a CNS-focused...
SAN FRANCISCO , May 23, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced the formation of Inheris Biopharma, Inc., a wholly-owned subsidiary of Nektar and a CNS-focused company. Inheris will be responsible for launch preparation and commercialization for N
Read more →NKTRNektar Therapeutics Announces Five Accepted Abstracts at 2019 American Society of Clinical Oncology's (ASCO) Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) today announced five abstracts accepted for presentation at the 55th Annual Meeting of the American Society of...
SAN FRANCISCO , May 15, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced five abstracts accepted for presentation at the 55 th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from May 31 to June 4, 2019 at the McCorm
Read more →NKTRNektar Therapeutics Reports Financial Results for the First Quarter of 2019
Nektar Therapeutics Reports Financial Results for the First Quarter of 2019 SAN FRANCISCO, May 8, 2019 - Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2019. Cash and investments in marketable securities at March
Read more →NKTRNektar to Announce Financial Results for the First Quarter 2019 on Wednesday, May 8, 2019, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2019 on Wednesday, May 8, 2019, after the close of...
SAN FRANCISCO , May 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the first quarter 2019 on Wednesday, May 8, 2019 , after the close of U.S.-based financial markets. Howard Robin , President and Chief Executive Officer, will h
Read more →NKTRNektar Therapeutics Presents Preclinical Data on its Immuno-Oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019 Nektar Therapeutics (Nasdaq: NKTR) today presented preclinical data on its immuno-oncology pipeline candidates, bempegaldesleukin (NKTR-214 or...
SAN FRANCISCO , April 2, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today presented preclinical data on its immuno-oncology pipeline candidates, bempegaldesleukin (NKTR-214 or bempeg), a CD122-preferential IL-2 pathway agonist, and NKTR-255, an IL-15 receptor agonis
Read more →NKTRVaccibody AS and Nektar Therapeutics Present New Preclinical Data from their Immuno-Oncology Collaboration at the American Association for Cancer Research (AACR) Annual Meeting 2019 Vaccibody AS and Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of new preclinical data for VB10.NEO, a personalized neoantigen...
OSLO, Norway and SAN FRANCISCO , April 1, 2019 /PRNewswire/ -- Vaccibody AS and Nektar Therapeutics (Nasdaq: NKTR ) today announced the presentation of new preclinical data for VB10.NEO, a personalized neoantigen cancer vaccine, combined with bempegaldesleukin (NKTR-214 or bempeg
Read more →NKTRNektar Therapeutics to Webcast Presentation at the Cowen and Company 39th Annual Health Care Conference Nektar Therapeutics (Nasdaq: NKTR) today announced that its Chief Scientific Officer, Jonathan Zalevsky, Ph.D., is scheduled to present at the Cowen...
SAN FRANCISCO , March 6, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that its Chief Scientific Officer, Jonathan Zalevsky , Ph.D., is scheduled to present at the Cowen and Company 39 th Annual Health Care Conference on Tuesday, March 12, 2019 at 9:20
Read more →NKTRNektar Therapeutics Presents Preliminary Immune Activation, Safety and Clinical Activity Data from the Ongoing Dose-Escalation Stage of the REVEAL Study at 2019 ASCO-SITC Meeting
Therapeutics Presents Preliminary Immune Activation, Safety and Clinical Activity Data from the Ongoing Dose-Escalation Stage of the REVEAL Study at 2019 ASCO-SITC Meeting FRANCISCO, March 1, 2019 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today announced early results f
Read more →NKTRNektar Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results
Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results FRANCISCO, Feb. 28, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2018. and investments in marketable secu
Read more →NKTRNektar Therapeutics Announces Several Preclinical Data Presentations for its Immuno-oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019 Nektar Therapeutics (Nasdaq: NKTR) today announced several preclinical data presentations for its immuno-oncology pipeline candidates,...
SAN FRANCISCO , Feb. 27, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced several preclinical data presentations for its immuno-oncology pipeline candidates, bempegaldesleukin* (NKTR-214), a CD122-preferential IL-2 pathway agonist, and NKTR-255, an IL-15 r
Read more →NKTRNektar Therapeutics to Webcast Conference Call for Analysts and Investors at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium Nektar Therapeutics (Nasdaq: NKTR) announced today that it will webcast an analyst and investor conference call with lead investigator of the REVEAL...
SAN FRANCISCO , Feb. 25, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that it will webcast an analyst and investor conference call with lead investigator of the REVEAL study, Dr. Adi Diab , and company management on Friday, March 1, 2019 at 3:00 p.m. P
Read more →NKTRNektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2018 on Thursday, February 28, 2019, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2018, on Thursday, February ...
SAN FRANCISCO , Feb. 21, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the fourth quarter and year-ended December 31, 2018 , on Thursday, February 28, 2019 , after the close of U.S.-based financial markets. Howard Robin , Preside
Read more →NKTRClinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Metastatic Urothelial Carcinoma Patients at the 2019 ASCO Genitourinary Cancers Symposium Analyst conference call with urothel
Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Metastatic Urothelial Carcinoma Patients at the 2019 ASCO Genitourinary Cancers Symposium conference call with urothelial cancer specialist to be held 2:00 p.m. Pacific Time today FRANCISCO,
Read more →NKTRNektar Therapeutics to Webcast Conference Call with Urothelial Cancer Specialist for Analysts & Investors at the 2019 ASCO Genitourinary Cancers Symposium Nektar Therapeutics (Nasdaq: NKTR) announced today that it will webcast an analyst and investor conference call with a urothelial cancer specialist...
SAN FRANCISCO , Feb. 11, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that it will webcast an analyst and investor conference call with a urothelial cancer specialist and company management on Friday, February 15, 2019 at 2:00 p.m. Pacific Time , durin
Read more →NKTRNektar Therapeutics' President and CEO, Howard Robin, To Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 37th Annual J.P....
SAN FRANCISCO , Dec. 27, 2018 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) President and Chief Executive Officer, Howard Robin , is scheduled to present at the upcoming 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 8, 2019 at 9:00 a.m.
Read more →NKTRNektar Appoints Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs Nektar Therapeutics (Nasdaq: NKTR) today announced the appointment of Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of...
SAN FRANCISCO , Nov. 14, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced the appointment of Wei Lin , M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs. In this role, Dr. Lin will lead development strategy and s
Read more →NKTRNektar Therapeutics Presents New Clinical and Preclinical Data for its Immuno-Oncology Pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation of new clinical and preclinical data for its I-O pipeline at the 2018 Society for...
SAN FRANCISCO , Nov. 9, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today a presentation of new clinical and preclinical data for its I-O pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting. New clinical study results from the PI
Read more →NKTRNektar Therapeutics Reports Financial Results for the Third Quarter of 2018
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2018 SAN FRANCISCO, November 7, 2018 - Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2018. Cash and investments in marketable securities a
Read more →NKTRNew Clinical Oncology Collaboration Between Nektar and Pfizer to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers Nektar Therapeutics (NASDAQ:NKTR) announced that it has entered into an oncology clinical collaboration with Pfizer Inc. (NYSE:PFE) to evaluate...
SAN FRANCISCO , Nov. 6, 2018 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced that it has entered into an oncology clinical collaboration with Pfizer Inc. (NYSE: PFE ) to evaluate several combination regimens in multiple cancer settings, including metastatic castrati
Read more →NKTRNektar Therapeutics to Host Webcast Conference Call with Melanoma Specialists for Analysts & Investors During 2018 Society for Immunotherapy of Cancer 33rd Annual Meeting Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with melanoma specialists and company...
SAN FRANCISCO , Nov. 6, 2018 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today that it will webcast an analyst and investor conference call with melanoma specialists and company management on Saturday, November 10, 2018 at 9:00 a.m. EST in Washington, D.C. durin
Read more →NKTRNektar to Announce Financial Results for the Third Quarter 2018 on Wednesday, November 7, 2018, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Wednesday, November 7, 2018, after the close of...
SAN FRANCISCO , Oct. 30, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the third quarter on Wednesday, November 7, 2018 , after the close of U.S.-based financial markets. Howard Robin , president and chief executive officer, will
Read more →NKTRNektar Therapeutics Announces Ten Abstracts Accepted for Presentation at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) today announced that ten clinical and preclinical data presentations across its immuno-oncology portfolio will be...
SAN FRANCISCO , Oct. 2, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that ten clinical and preclinical data presentations across its immuno-oncology portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting,
Read more →NKTRNektar Therapeutics Strengthens Board of Directors with Appointment of Veteran Biotechnology Executive Karin Eastham Nektar Therapeutics (Nasdaq: NKTR) today announced that it has appointed Karin Eastham as an independent director to its Board of Directors. Ms....
SAN FRANCISCO , Oct. 1, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that it has appointed Karin Eastham as an independent director to its Board of Directors. Ms. Eastham brings more than 35 years of experience as both an executive and independent dire
Read more →NKTRNektar Therapeutics Reports Financial Results for the Second Quarter of 2018
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2018 SAN FRANCISCO, Aug 8, 2018/PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2018. Cash and investments in marketable secur
Read more →NKTRNektar to Announce Financial Results for the Second Quarter 2018 on Wednesday, August 8, 2018, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Wednesday, August 8, 2018, after the close of...
SAN FRANCISCO , Aug. 1, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the second quarter on Wednesday, August 8, 2018, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will hos
Read more →NKTRNektar Therapeutics Announces New Drug Application for NKTR-181 Accepted for Review by FDA Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review the company's...
SAN FRANCISCO , July 30, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review the company's New Drug Application (NDA) for NKTR-181 for the treatment of chronic low back pain in
Read more →NKTRNew Data for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy, Presented at College on Problems of Drug Dependence 80th Annual Scientific Meeting Nektar Therapeutics (Nasdaq: NKTR) today announced that new clinical and preclinical data for NKTR-181 were presented this week at the 80th Annual...
SAN FRANCISCO , June 14, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that new clinical and preclinical data for NKTR-181 were presented this week at the 80th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD) in San Diego,
Read more →NKTRNektar to Webcast Presentation at the Jefferies 2018 Healthcare Conference in New York Nektar Therapeutics' (Nasdaq: NKTR) Senior Vice President and Chief Scientific Officer, Jonathan Zalevsky, Ph.D., is scheduled to present at the...
SAN FRANCISCO , June 5, 2018 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) Senior Vice President and Chief Scientific Officer, Jonathan Zalevsky, Ph.D., is scheduled to present at the upcoming Jefferies 2018 Healthcare Conference in New York City on Wednesday, June 6, 2018
Read more →NKTRNektar Therapeutics Announces Submission of a New Drug Application to the U.S. FDA for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy Nektar Therapeutics (Nasdaq: NKTR) today announced submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for...
SAN FRANCISCO , May 31, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for NKTR-181, a new molecular entity (NME) and the first analgesic opioid molecule to exhibit
Read more →NKTRNektar Therapeutics Announces Six Abstracts Accepted for Presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) today announced that new clinical and preclinical data will be presented at the upcoming 2018 American Society of...
SAN FRANCISCO , May 16, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that new clinical and preclinical data will be presented at the upcoming 2018 American Society of Clinical Oncology Annual Meeting, which is being held from June 1 to June 5, 2018 , a
Read more →NKTRNektar Therapeutics Reports Financial Results for the First Quarter of 2018
Nektar Therapeutics Reports Financial Results for the First Quarter of 2018 SAN FRANCISCO, May 10, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2018. Cash and investments in marketable securi
Read more →NKTRNektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus Nektar Therapeutics (NASDAQ: NKTR) today announced that it has commenced dosing patients with systemic lupus erythematosus (SLE) in a Phase 1b...
SAN FRANCISCO , May 8, 2018 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced that it has commenced dosing patients with systemic lupus erythematosus (SLE) in a Phase 1b clinical study evaluating NKTR-358, a first-in-class regulatory T cell stimulator. NKTR-358
Read more →NKTRNektar to Announce Financial Results for the First Quarter 2018 on Thursday, May 10, 2018, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 10, 2018, after the close of U.S.-based ...
SAN FRANCISCO , May 3, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the first quarter on Thursday, May 10, 2018, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a c
Read more →NKTRNektar Therapeutics to Host Analyst & Investor Event at 2018 ASCO Annual Meeting Nektar Therapeutics (NASDAQ:NKTR) announced today that it will host an analyst and investor event with clinical investigators on Saturday, June 2,...
SAN FRANCISCO , April 30, 2018 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today that it will host an analyst and investor event with clinical investigators on Saturday, June 2, 2018 at 6:45 p.m. CDT in Chicago, IL during the 2018 American Society of Clinical On
Read more →NKTRNew Oncology Clinical Collaboration between Nektar and Takeda to Evaluate Combination of NKTR-214, a CD122-biased Agonist, and TAK-659, a Dual SYK and FLT-3 Inhibitor, in Liquid and Solid Tumors Nektar Therapeutics (NASDAQ:NKTR) announced today that it has entered into a new clinical collaboration with Takeda Pharmaceutical Company Limited to ...
SAN FRANCISCO , April 24, 2018 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today that it has entered into a new clinical collaboration with Takeda Pharmaceutical Company Limited to evaluate Nektar's investigational medicine, NKTR-214, with Takeda's investigation
Read more →NKTRNektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2018 Nektar Therapeutics (Nasdaq: NKTR) today announced that it is presenting new preclinical data for its immuno-oncology programs at the American...
SAN FRANCISCO , April 15, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that it is presenting new preclinical data for its immuno-oncology programs at the American Association for Cancer Research (AACR) Annual Meeting 2018. Nektar researchers and collab
Read more →NKTRNektar to Webcast Presentation at the Cowen and Company 38th Annual Health Care Conference in Boston Nektar Therapeutics' (Nasdaq: NKTR) Senior Vice President and Chief Scientific Officer, Jonathan Zalevsky, Ph.D., is scheduled to present at the...
SAN FRANCISCO , March 7, 2018 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) Senior Vice President and Chief Scientific Officer, Jonathan Zalevsky , Ph.D., is scheduled to present at the upcoming Cowen and Company 38 th Annual Health Care Conference in Boston on Wednesday,
Read more →NKTRNektar Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results
Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results SAN FRANCISCO, March 1, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2017. and investments in marketable s
Read more →NKTRNektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2017 on Thursday, March 1, 2018, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2017, on Thursday, March 1, ...
SAN FRANCISCO , Feb. 21, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the fourth quarter and year-ended December 31, 2017, on Thursday, March 1, 2018, after the close of U.S.-based financial markets. Howard Robin, president and
Read more →NKTRBristol-Myers Squibb and Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar s CD122-biased Agonist, NKTR-214 Collaboration to evaluate the full-potential of NKTR-214 plus Opdivo
Bristol-Myers Squibb and Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar s CD122-biased (NEW YORK and SAN FRANCISCO, February 14, 2018) - Bristol-Myers Squibb Company (NYSE:BMY) and Nektar Therapeutics (Nasdaq: NKTR) announced today
Read more →NKTRNektar to Webcast Presentation at the Piper Jaffray 29th Annual Healthcare Conference in New York City Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation will be webcast at the upcoming Piper Jaffray 29th Annual...
SAN FRANCISCO , Nov. 27, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that its corporate presentation will be webcast at the upcoming Piper Jaffray 29 th Annual Healthcare Conference in New York City on Tuesday, November 28, 2017 at 5:10 p.m. ET. The
Read more →NKTRNektar Announces Key Executive Promotions to Drive the Continued Growth of the Company's Immuno-Oncology Pipeline Nektar Therapeutics (Nasdaq: NKTR) announced today several promotions on its executive leadership team: Stephen Doberstein, Ph.D., has been promoted...
SAN FRANCISCO , Nov. 22, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today several promotions on its executive leadership team: "I am exceptionally pleased to announce today's promotions which highlight the talent, skill set and extensive achievements of o
Read more →NKTRFirst Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017 Nektar Therapeutics (Nasdaq: NKTR) and Bristol-Myers Squibb (NYSE: BMY) today announced the first presentation of data from the PIVOT-02 Phase 1/2...
NATIONAL HARBOR, Md., Nov. 11, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) and Bristol-Myers Squibb (NYSE: BMY ) today announced the first presentation of data from the PIVOT-02 Phase 1/2 Study, which is designed to evaluate the combination of Bristol-Myers Squibb's
Read more →NKTRNektar to Webcast Presentation at Jefferies 2017 London Healthcare Conference Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation will be webcast at the upcoming Jefferies 2017 London Healthcare...
SAN FRANCISCO , Nov. 10, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that its corporate presentation will be webcast at the upcoming Jefferies 2017 London Healthcare Conference in London on Wednesday, November 15, 2017 at 10:00 a.m. GMT. The presenta
Read more →NKTRNektar Therapeutics Reports Financial Results for the Third Quarter of 2017
Reports Financial Results for the Third Quarter of 2017 SAN FRANCISCO, Nov. 7, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2017. Cash and investments in marketable securities at Septembe
Read more →NKTRNew Data Featuring Nektar Therapeutics' Wholly-Owned Immuno-Oncology Pipeline to be Presented at the 2017 Society for Immunotherapy of Cancer 32nd Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) today announced that new clinical data will be presented for NKTR-214, Nektar's lead immuno-oncology candidate, a...
SAN FRANCISCO , Nov. 7, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that new clinical data will be presented for NKTR-214, Nektar's lead immuno-oncology candidate, a CD122-biased agonist, at the Society for Immunotherapy of Cancer (SITC) Annual Meetin
Read more →NKTRNektar to Announce Financial Results for the Third Quarter of 2017 on Tuesday, November 7, 2017, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2017, on Tuesday, November 7, 2017,...
SAN FRANCISCO , Oct. 31, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the third quarter ended September 30, 2017, on Tuesday, November 7, 2017, after the close of U.S.-based financial markets. Howard Robin, president and chief e
Read more →NKTRNektar Therapeutics Appoints Biotechnology Executive Jeff Ajer as New Board Member
Therapeutics Appoints Biotechnology Executive Jeff Ajer as New Board Member FRANCISCO, Sept. 21, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that Jeff Ajer, Executive Vice President and Chief Commercial Officer of BioMarin, has been appointed as an i
Read more →NKTRNektar Therapeutics Announces Seven Abstracts Accepted for Presentation at 2017 Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) today announced that new data across its wholly-owned immuno-oncology (I-O) portfolio will be presented at the...
SAN FRANCISCO , Sept. 20, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that new data across its wholly-owned immuno-oncology (I-O) portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, which is being hel
Read more →NKTRNektar Therapeutics Initiates PROPEL Clinical Study to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with TECENTRIQ® (atezolizumab) or KEYTRUDA® (pembrolizumab) Nektar Therapeutics (Nasdaq: NKTR) today announced that it has begun dosing in the PROPEL clinical study which will evaluate the efficacy and safety...
SAN FRANCISCO , Sept. 12, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that it has begun dosing in the PROPEL clinical study which will evaluate the efficacy and safety of NKTR-214, the company's lead immuno-oncology candidate in combination with appro
Read more →NKTRNektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2017 Morgan Stanley Global Healthcare Conference in New York City Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 2017 Morgan...
SAN FRANCISCO , Sept. 6, 2017 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 2017 Morgan Stanley Global Healthcare Conference in New York City on Tuesday, September 12, 2017 at 1
Read more →NKTRNektar Therapeutics Presents Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2017 PAINWeek® Nektar Therapeutics (Nasdaq: NKTR) today presented clinical data from the SUMMIT-07 Phase 3 study of NKTR-181, a first-in-class opioid analgesic to...
SAN FRANCISCO , Sept. 6, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today presented clinical data from the SUMMIT-07 Phase 3 study of NKTR-181, a first-in-class opioid analgesic to treat chronic pain, at the 2017 PAINWeek ® Conference in Las Vegas taking place Septe
Read more →NKTRNektar Therapeutics to Present Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at PAINWeek® Nektar Therapeutics (Nasdaq: NKTR) will present clinical data from the SUMMIT-07 Phase 3 efficacy and safety study of NKTR-181, a first-in-class...
SAN FRANCISCO , Aug. 30, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will present clinical data from the SUMMIT-07 Phase 3 efficacy and safety study of NKTR-181, a first-in-class opioid analgesic to treat chronic pain, at the upcoming 2017 PAINWeek® Conference in Las
Read more →NKTRNektar Therapeutics Reports Financial Results for the Second Quarter of 2017
Therapeutics Reports Financial Results for the Second Quarter of 2017 FRANCISCO, Aug. 8, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2017. and investments in marketable securities at June 30
Read more →NKTRNektar to Announce Financial Results for the Second Quarter of 2017 on Tuesday, August 8, 2017, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2017, on Tuesday, August 8, 2017, after...
SAN FRANCISCO , Aug. 2, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the second quarter ended June 30, 2017, on Tuesday, August 8, 2017, after the close of U.S.-based financial markets. Howard Robin, president and chief executiv
Read more →NKTRLilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy INDIANAPOLIS & SAN FRANCISCO - Eli Lilly and Company (NYSE: LLY) and Nektar Therapeutics ( NASDAQ: NKTR) h
Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy INDIANAPOLIS & SAN FRANCISCO - Eli Lilly and Company (NYSE: LLY) and Nektar Therapeutics (NASDAQ: NKTR) have announced a strategic collaboration to co-develop NK
Read more →NKTRNektar Announces Topline Data from Human Abuse Potential Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain NKTR-181 shows significantly less abuse potential compared to oxycodone Analyst C
Nektar Announces Topline Data from Human Abuse Potential Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain NKTR-181 shows significantly less abuse potential compared to oxycodone Analyst Conference Call and Webcast Today at 5:45 a.m. PDT/8:45
Read more →NKTRNektar Presents New Preclinical Data for NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London Nektar Therapeutics (NASDAQ: NKTR) today announced positive preclinical results for NKTR-358, a first-in-class resolution therapeutic for autoimmune...
SAN FRANCISCO , July 10, 2017 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced positive preclinical results for NKTR-358, a first-in-class resolution therapeutic for autoimmune disease. The new preclinical data demonstrate that treatment with NKTR-358 induces p
Read more →NKTRNektar to Webcast Presentation at Jefferies 2017 Global Healthcare Conference in New York City Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation will be webcast at the upcoming Jefferies 2017 Global Healthcare...
SAN FRANCISCO , June 6, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that its corporate presentation will be webcast at the upcoming Jefferies 2017 Global Healthcare Conference in New York City on Wednesday, June 7, 2017 at 9:30 a.m. Eastern time . Th
Read more →NKTRNektar Presents New Clinical Data from Two Studies of NKTR-214, a CD122-Biased Agonist, at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) today announced that it presented new findings from two Phase 1 clinical studies of NKTR-214, Nektar's lead...
CHICAGO and SAN FRANCISCO , June 5, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that it presented new findings from two Phase 1 clinical studies of NKTR-214, Nektar's lead immuno-oncology candidate, a CD122-biased agonist, at the 2017 American Society
Read more →NKTRNew Research Collaboration between Nektar and Takeda to Explore Combination Cancer Therapy Approaches with NKTR-214, a CD122-Biased Agonist, and Five Takeda Cancer Therapy Compounds Nektar Therapeutics (NASDAQ: NKTR) announced today that Takeda Pharmaceutical Company Limited (TSE: 4502) and Nektar have entered into a research...
SAN FRANCISCO , May 22, 2017 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today that Takeda Pharmaceutical Company Limited ( TSE: 4502 ) and Nektar have entered into a research collaboration to explore the combination of Nektar's lead immuno-oncology candidate, t
Read more →NKTRNektar Therapeutics Announces Data Presentations at ASCO 2017 Nektar Therapeutics (Nasdaq: NKTR) today announced its presence at the upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting,...
SAN FRANCISCO , May 18, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced its presence at the upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, where it will share updated data from clinical studies of NKTR-214. ASCO will take place
Read more →NKTRNektar to Webcast Presentation at UBS Global Healthcare Conference 2017 in New York Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation will be webcast at the upcoming UBS Global Healthcare Conference...
SAN FRANCISCO , May 15, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that its corporate presentation will be webcast at the upcoming UBS Global Healthcare Conference on Monday, May 22, 2017 at 1:30 p.m. Eastern time . The presentation will be accessib
Read more →NKTRNektar Therapeutics Reports Financial Results for the First Quarter of 2017
Nektar Therapeutics Reports Financial Results for the First Quarter of 2017 SAN FRANCISCO, May 9, 2017 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2017. Cash and investments in marketable securit
Read more →NKTRNektar Appoints Brian L. Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology Program Nektar Therapeutics (Nasdaq: NKTR) today announced the appointment of Brian Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology...
SAN FRANCISCO , May 3, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced the appointment of Brian Kotzin , M.D. as Head of Clinical Development for Nektar's Immunology Program. In this newly-created role, Dr. Kotzin will lead clinical development for NKTR-3
Read more →NKTRNektar to Announce Financial Results for the First Quarter of 2017 on Tuesday, May 9, 2017, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2017, on Tuesday, May 9, 2017, after the ...
SAN FRANCISCO , May 2, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the first quarter ended March 31, 2017, on Tuesday, May 9, 2017, after the close of U.S.-based financial markets. Howard Robin, president and chief executive of
Read more →NKTRNektar Therapeutics to Host Analyst & Investor Event at 2017 ASCO Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host an analyst and investor event with clinical investigators on Saturday, June 3,...
SAN FRANCISCO , April 20, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that it will host an analyst and investor event with clinical investigators on Saturday, June 3, 2017 at 6:00 pm CDT in Chicago, IL during the 2017 American Society of Clinical Onco
Read more →NKTRNektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) today announced five preclinical data presentations for its immuno-oncology programs made at the American...
SAN FRANCISCO , April 4, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced five preclinical data presentations for its immuno-oncology programs made at the American Association for Cancer Research (AACR) Annual Meeting 2017. The presentations featured new p
Read more →NKTRNektar Therapeutics Initiates Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, Being Developed for the Treatment of Immune and Inflammatory Disorders Nektar Therapeutics (NASDAQ: NKTR) today announced that it has begun dosing in a Phase 1 clinical study evaluating NKTR-358, the company's new...
SAN FRANCISCO , March 27, 2017 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced that it has begun dosing in a Phase 1 clinical study evaluating NKTR-358, the company's new biologic therapy, which is being developed to treat a wide range of auto-immune diseases
Read more →NKTRNKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from the SUMMIT-07 Phase 3 efficacy study of NKTR-181, a first-in-class opioid...
SAN FRANCISCO , March 20, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced positive results from the SUMMIT-07 Phase 3 efficacy study of NKTR-181, a first-in-class opioid analgesic. NKTR-181 is a new chemical entity (NCE) that is the first full mu-opioid a
Read more →NKTRMeets Primary and Secondary Endpoints in Phase 3
Meets Primary and Secondary Endpoints in Phase 3 Study in Chronic Pain Significantly Reduced Pain in Patients with Moderate to Severe Efficacy Endpoint Achieved (p=0.0019) Conference Call and Webcast at 5:45 a.m. PDT/8:45 a.m. EDT San Francisco, March 20, 2017 - Nektar The
Read more →NKTRNektar to Webcast Presentation at Cowen and Company's 37th Annual Health Care Conference in Boston Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation will be webcast at the upcoming Cowen and Company 37th Annual...
SAN FRANCISCO , March 2, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that its corporate presentation will be webcast at the upcoming Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 11:20 a.m. Eastern time . The prese
Read more →NKTRNektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results
Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results SAN FRANCISCO, March 1, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2016. Cash and investments in
Read more →NKTRNektar Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) today announced five data presentations will be delivered at the upcoming American Association for Cancer Research ...
SAN FRANCISCO , March 1, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced five data presentations will be delivered at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which will be held April 1-5, 2017 at the Walter E. Washingt
Read more →NKTRNektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2016 on Wednesday, March 1, 2017, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2016, on Wednesday, March...
SAN FRANCISCO , Feb. 22, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the fourth quarter and year-ended December 31, 2016 , on Wednesday, March 1, 2017 , after the close of U.S.-based financial markets. Howard Robin , president
Read more →NKTRClinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium Nektar Therapeutics (Nasdaq: NKTR) today announced that positive Phase 1 clinical data for Nektar's lead immuno-oncology agent, NKTR-214, in patients ...
SAN FRANCISCO and ORLANDO, Fla. , Feb. 18, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that positive Phase 1 clinical data for Nektar's lead immuno-oncology agent, NKTR-214, in patients with renal cell carcinoma (RCC) were presented at ASCO GU 2017. N
Read more →NKTRNektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 35th Annual J.P....
SAN FRANCISCO , Jan. 5, 2017 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) President and Chief Executive Officer, Howard W. Robin , is scheduled to present at the upcoming 35th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 10, 2017 at 2:00 p
Read more →NKTRNektar Therapeutics to Present at Jefferies 2016 Global Healthcare Conference in London Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its corporate presentation at the Jefferies 2016 London...
SAN FRANCISCO , Nov. 11, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that the company will be webcasting its corporate presentation at the Jefferies 2016 London Healthcare Conference to be held at the Waldorf Hilton London, on Wednesday, November 16,
Read more →NKTRNektar Therapeutics Presents New Clinical Data from Ongoing Phase 1 Dose-Escalation Study of NKTR-214 at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) today announced that new Phase 1 clinical data for Nektar's lead immuno-oncology agent, NKTR-214, were presented...
SAN FRANCISCO , Nov. 9, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that new Phase 1 clinical data for Nektar's lead immuno-oncology agent, NKTR-214, were presented at the SITC 2016 Annual Meeting. NKTR-214 is an investigational immuno-stimulatory the
Read more →NKTRNektar Therapeutics Reports Financial Results for the Third Quarter of 2016
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2016 SAN FRANCISCO, Nov. 3, 2016 /PRNewswire/ Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September Cash and investments in marketable securities at Se
Read more →NKTRNektar Therapeutics Announces Upcoming Presentations at the 2016 Society for Immunotherapy of Cancer Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) today announced five data presentations will be delivered at the upcoming Society for Immunotherapy of Cancer...
SAN FRANCISCO , Oct. 28, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced five data presentations will be delivered at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, which will be held November 9-13, 2016 at the Gaylord National Ho
Read more →NKTRNektar to Hold Investor & Analyst Event at 2016 Society for Immunotherapy of Cancer Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host an investor and analyst event at the upcoming Society for Immunotherapy of...
SAN FRANCISCO , Oct. 28, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that it will host an investor and analyst event at the upcoming Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting in National Harbor, Maryland. The event will be held on
Read more →NKTRNektar to Announce Financial Results for the Third Quarter 2016 on Thursday, November 3, 2016, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2016, on Thursday, November 3, 2016, ...
SAN FRANCISCO , Oct. 27, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the third quarter ended September 30, 2016 , on Thursday, November 3, 2016 , after the close of U.S.-based financial markets. Howard Robin , president and chi
Read more →NKTRNektar Therapeutics Prices Public Offering of Shares of Common Stock Nektar Therapeutics (Nasdaq: NKTR) ( Nektar ) today announced the pricing of its previously announced underwritten public offering of $175.5 million...
SAN FRANCISCO , Oct. 18, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) ("Nektar") today announced the pricing of its previously announced underwritten public offering of $175.5 million in aggregate gross proceeds, or 13,000,000 shares of its common stock at a public of
Read more →NKTRNektar Therapeutics Announces Public Offering of Shares of Common Stock
Nektar Therapeutics Announces Public Offering of Shares of Common Stock SAN FRANCISCO, October 17, 2016 Nektar Therapeutics (Nasdaq: NKTR) ( Nektar ) today announced that it has commenced an underwritten public offering of $175 million of shares of its common stock. In connecti
Read more →NKTRNektar Therapeutics to Host Investor & Analyst Conference Call to Discuss New Clinical Collaboration with Bristol-Myers Squibb Nektar Therapeutics (Nasdaq: NKTR) announced that it will host a conference call to discuss today's announcement of the new clinical collaboration...
SAN FRANCISCO , Sept. 27, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced that it will host a conference call to discuss today's announcement of the new clinical collaboration with Bristol-Myers Squibb. The call will begin at 9:00 a.m. Eastern Time (ET)/ 6:00 a
Read more →NKTRBristol-Myers Squibb and Nektar Therapeutics Announce Oncology Clinical Collaboration to Evaluate the Combination of Opdivo (nivolumab) and NKTR-214 New collaboration will explore the potential benefits of combining Bris
Bristol-Myers Squibb and Nektar Therapeutics Announce Oncology Clinical Collaboration to Evaluate the Combination of Opdivo (nivolumab) and NKTR-214 New collaboration will explore the potential benefits of combining Bristol-Myers Squibb's anti-PD-1 antibody with Nektar's CD122
Read more →NKTRNektar Therapeutics Reports Financial Results for the Second Quarter of 2016
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2016 SAN FRANCISCO, Aug. 3, 2016 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2016. Cash and investments in marketable secur
Read more →NKTRNektar to Announce Financial Results for the Second Quarter 2016 on Wednesday, August 3, 2016, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2016, on Wednesday, August 3, 2016,...
SAN FRANCISCO , July 27, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the second quarter ended June 30, 2016 , on Wednesday, August 3, 2016, after the close of U.S.-based financial markets. Howard Robin , president and chief exe
Read more →NKTRPreclinical Data Presented at ASCO 2016 Annual Meeting Demonstrate that Single-Agent NKTR-214 Produces a Large Increase in Tumor-Infiltrating Lymphocytes to Provide Durable Anti-Tumor Activity Nektar Therapeutics (NASDAQ: NKTR) today announced new preclinical data for NKTR-214, an immuno-stimulatory CD-122 biased cytokine currently being...
SAN FRANCISCO , June 6, 2016 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced new preclinical data for NKTR-214, an immuno-stimulatory CD-122 biased cytokine currently being evaluated in cancer patients with solid tumors in a Phase 1/2 clinical trial being cond
Read more →NKTRNektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2016 Global Healthcare Conference in New York City Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming Jefferies 2016...
SAN FRANCISCO , June 2, 2016 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) President and Chief Executive Officer, Howard W. Robin , is scheduled to present at the upcoming Jefferies 2016 Global Healthcare Conference in New York City on Wednesday, June 8, 2016 at 11:30 a.m.
Read more →NKTRNektar Therapeutics Announces Executive Management Promotions John Nicholson named Senior Vice President & Chief Operating Officer of Nektar; Gil M. Labrucherie named Senior Vice President & Chief Financial Officer of Ne
Therapeutics Announces Executive Management Promotions Nicholson named Senior Vice President & Chief Operating Officer of Nektar; Gil M. Labrucherie named Senior Vice President & Chief Financial Officer of Nektar Francisco, CA, June 2, 2016 - Nektar Therapeutics (NASDAQ: NKTR)
Read more →NKTRNektar Therapeutics and Daiichi Sankyo Europe GmbH Sign European Licensing Agreement for ONZEALD™ (etirinotecan pegol), an Investigational Drug Candidate Being Developed to Treat Patients with Advanced Breast Cancer and Brain Metastases Nektar Therapeutics (Nasdaq: NKTR) today announced that it has entered into an agreement with Daiichi Sankyo Europe for Nektar's investigational drug ...
SAN FRANCISCO , June 1, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that it has entered into an agreement with Daiichi Sankyo Europe for Nektar's investigational drug therapy, ONZEALD (etirinotecan pegol, NKTR-102), which has completed a Phase 3 clini
Read more →NKTRNektar Therapeutics Reports Financial Results for the First Quarter of 2016
Nektar Therapeutics Reports Financial Results for the First Quarter of 2016 SAN FRANCISCO, May 3, 2016 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2016. Cash and investments in marketable securit
Read more →NKTRNektar to Announce Financial Results for the First Quarter 2016 on Tuesday, May 3, 2016, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2016, on Tuesday, May 3, 2016, after the ...
SAN FRANCISCO , April 28, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the first quarter ended March 31, 2016 , on Tuesday, May 3, 2016 , after the close of U.S.-based financial markets. Howard Robin , president and chief execut
Read more →NKTRPreclinical Data Presented at AACR Demonstrate that Combining NKTR-214 with Checkpoint Blockade is Superior to Dual Checkpoint Inhibition in Increasing Clonality of the T Cell Receptor (TCR) Repertoire and T Cell Tumor Infiltration Nektar Therapeutics (NASDAQ: NKTR) today announced new preclinical data for the company's investigational immuno-stimulatory cytokine therapy,...
SAN FRANCISCO , April 18, 2016 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced new preclinical data for the company's investigational immuno-stimulatory cytokine therapy, NKTR-214, which demonstrate both its activity as a single-agent and its synergistic activ
Read more →NKTRNektar Therapeutics to Present at Cowen and Company's 36th Annual Health Care Conference in Boston, MA Nektar Therapeutics (Nasdaq: NKTR) is scheduled to present at the upcoming Cowen and Company 36th Annual Health Care Conference in Boston,...
SAN FRANCISCO , March 3, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) is scheduled to present at the upcoming Cowen and Company 36th Annual Health Care Conference in Boston, Massachusetts on Wednesday, March 9, 2016 at 8:40 a.m. Eastern time . The presentation will b
Read more →NKTRNektar Therapeutics Reports Fourth Quarter and Year-End 2015 Financial Results
Nektar Therapeutics Reports Fourth Quarter and Year-End 2015 Financial Results SAN FRANCISCO, March 1, 2016 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2015. Cash and investments in
Read more →NKTRNektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2015 on Tuesday, March 1, 2016, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2015, on Tuesday, March 1,...
SAN FRANCISCO , Feb. 26, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the fourth quarter and year-ended December 31, 2015 , on Tuesday, March 1, 2016 , after the close of U.S.-based financial markets. Howard Robin , president an
Read more →NKTRBaxalta Announces Submission of Supplemental BLAs to Expand Use of ADYNOVATE to Pediatric Patients and Surgical Settings Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases ...
BANNOCKBURN, Ill. , Feb. 25, 2016 /PRNewswire/ -- Baxalta Incorporated (NYSE: BXLT ), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has submitted supplemental
Read more →NKTRNektar Publishes Pre-clinical Results for NKTR-214, an Investigational CD122-Biased Immune-Stimulatory Cytokine for the Treatment of Cancer in Clinical Cancer Research Nektar Therapeutics (Nasdaq: NKTR) today announced the publication in Clinical Cancer Research of pre-clinical findings for NKTR-214. The paper,...
SAN FRANCISCO , Feb. 1, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced the publication in Clinical Cancer Research of pre-clinical findings for NKTR-214. The paper, titled " NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tum
Read more →NKTRNektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, CA Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 34th Annual J.P....
SAN FRANCISCO , Jan. 6, 2016 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) President and Chief Executive Officer, Howard W. Robin , is scheduled to present at the upcoming 34th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 12, 2016 at 11:00
Read more →NKTRBaxalta's ADYNOVATE Meets Endpoints in Phase 3 Study of Hemophilia A Patients Under 12 Years of Age Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan...
BANNOCKBURN, Ill. , Dec. 21, 2015 /PRNewswire/ -- Baxalta Incorporated (NYSE: BXLT ), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase 3 cli
Read more →NKTRNektar Announces First Patient Dosed in Phase 1/2 Clinical Study of NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine Nektar Therapeutics (NASDAQ:NKTR) today announced that dosing has commenced in the Phase 1/2 clinical study evaluating the efficacy and safety of...
SAN FRANCISCO , Dec. 8, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced that dosing has commenced in the Phase 1/2 clinical study evaluating the efficacy and safety of NKTR-214 in the treatment of solid tumors. NKTR-214 is a novel CD122-biased cytokine de
Read more →NKTRNektar Therapeutics to Present at Oppenheimer 26th Annual Healthcare Conference in New York Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its corporate presentation at the Oppenheimer 26th Annual...
SAN FRANCISCO , Dec. 8, 2015 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that the company will be webcasting its corporate presentation at the Oppenheimer 26th Annual Healthcare Conference to be held at The Westin New York Grand Central, on Wednesday, Dece
Read more →NKTRBaxalta Presents Additional Data on Newly-Approved ADYNOVATE and Plans for New Indications During 57th American Society of Hematology (ASH) Annual Meeting Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan...
BANNOCKBURN, Ill. , Dec. 7, 2015 /PRNewswire/ -- Baxalta Incorporated (NYSE: BXLT ), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, has showcased data on the clinical experience with
Read more →NKTRBaxalta Announces U.S. Availability of ADYNOVATE, A New Treatment for Adult Patients with Hemophilia A With a Simple, Twice-Weekly Dosing Schedule Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan...
BANNOCKBURN, Ill. , Nov. 30, 2015 /PRNewswire/ -- Baxalta Incorporated (NYSE: BXLT ), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved medical conditions, today announced the launch and first shipm
Read more →NKTRNektar Therapeutics to Present at Jefferies Autumn 2015 Global Healthcare Conference in London Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its corporate presentation at the Jefferies Autumn 2015 Global ...
SAN FRANCISCO , Nov. 17, 2015 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that the company will be webcasting its corporate presentation at the Jefferies Autumn 2015 Global Healthcare Conference to be held at the May Fair Hotel, London , on Thursday, Novem
Read more →NKTRBaxalta to Advance Care for Hemophilia A patients with FDA Approval of ADYNOVATE, a Simple, Twice-weekly Treatment to Reduce Bleeds Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan...
BANNOCKBURN, Ill. , Nov. 16, 2015 /PRNewswire/ -- Baxalta Incorporated (NYSE: BXLT ), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that the U.S. Food and Drug Admini
Read more →NKTRNektar Therapeutics Reports Financial Results for the Third Quarter of 2015
Therapeutics Reports Financial Results for the Third Quarter of 2015 FRANCISCO, Nov. 5, 2015 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2015. and investments in marketable securities at Sept
Read more →NKTRNektar to Announce Financial Results for the Third Quarter 2015 on Thursday, November 5, 2015, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2015 on Thursday, November 5, 2015,...
SAN FRANCISCO , Oct. 29, 2015 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the third quarter ended September 30, 2015 on Thursday, November 5, 2015 , after the close of U.S.-based financial markets. Howard Robin , president and chief
Read more →NKTRNektar Reports on Advancements with Pain and Oncology Clinical Pipeline at Investor and Analyst R&D Day Nektar Therapeutics (Nasdaq: NKTR) will present an overview of the Company's pain and oncology portfolio during an Investor and Analyst R&D Day being ...
SAN FRANCISCO , Oct. 8, 2015 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will present an overview of the Company's pain and oncology portfolio during an Investor and Analyst R&D Day being hosted today from 12:30 - 3:30 p.m. Eastern Time in New York City . Leading experts
Read more →NKTRNektar Submits Investigational New Drug Application (IND) for NKTR-214 To Treat Solid Tumor Malignancies Nektar Therapeutics (NASDAQ:NKTR) today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug...
SAN FRANCISCO , Oct. 7, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NKTR-214, its lead immuno-oncology candidate. NKTR-214 is a CD12
Read more →NKTRNektar Closes Direct Private Placement with TPG Special Situations Partners of $250 Million of Senior Secured Notes Due in 2020
Nektar Closes Direct Private Placement with TPG Special Situations Partners of $250 Million of Senior Secured Notes Due in 2020 SAN FRANCISCO, Oct. 6, 2015 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the closing of a direct private placement of $250 mill
Read more →NKTRNektar to Host Research & Development Day for Analysts and Investors on October 8th Nektar Therapeutics (NASDAQ: NKTR) today announced that it will host a Research and Development (R&D) Day for analysts and investors on Thursday,...
SAN FRANCISCO , Oct. 1, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced that it will host a Research and Development (R&D) Day for analysts and investors on Thursday, October 8 , 2015. The event is scheduled to take place from 12:30 - 3:30 p.m. Eastern Ti
Read more →NKTRNektar Presents Data Demonstrating that NKTR-214, a CD122-Biased Immunostimulatory Cytokine, Induces Durable and Specific Anti-Tumor Immunity As a Single-Agent and When Combined with Checkpoint Inhibitors in Preclinical Models Nektar Therapeutics (NASDAQ: NKTR) today announced positive preclinical results for NKTR-214, a CD122-biased cytokine designed to preferentially...
SAN FRANCISCO , Sept. 21, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced positive preclinical results for NKTR-214, a CD122-biased cytokine designed to preferentially stimulate the production and maintenance of tumor-killing T cells which are found natur
Read more →NKTRNektar Announces Receipt of $40 Million Milestone Payment Resulting from First Commercial Sale of MOVENTIG® (naloxegol) Tablets in Major European Market Nektar Therapeutics (NASDAQ: NKTR) announced today that it has received a $40 million cash payment under a license agreement with AstraZeneca. The...
SAN FRANCISCO , Sept. 1, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today that it has received a $40 million cash payment under a license agreement with AstraZeneca. The payment was triggered by the first commercial sale of MOVENTIG (naloxegol) in Germany
Read more →NKTRNektar Therapeutics Reports Financial Results for the Second Quarter of 2015
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2015 SAN FRANCISCO, Calif., August 5, 2015 -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2015. Cash and investments in marketable securi
Read more →NKTRNektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2015 on Wednesday, August 5, 2015, after ...
SAN FRANCISCO , July 29, 2015 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the second quarter ended June 30, 2015 on Wednesday, August 5, 2015 , after the close of U.S.-based financial markets. Howard Robin , president and chief exec
Read more →NKTRBaxalta's BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A Nektar Therapeutics (Nasdaq: NKTR) reported that partner Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering...
SAN FRANCISCO , July 16, 2015 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) reported that partner Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today anno
Read more →NKTRNektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine Nektar Therapeutics (NASDAQ:NKTR) and The University of Texas MD Anderson Cancer Center today announced a research collaboration that includes a...
SAN FRANCISCO , June 2, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) and The University of Texas MD Anderson Cancer Center today announced a research collaboration that includes a Phase 1/2 clinical study to evaluate NKTR-214, a CD122-biased cytokine designed to prefe
Read more →NKTRNektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2015 Global Healthcare Conference in New York City Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming Jefferies 2015...
SAN FRANCISCO , May 28, 2015 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) President and Chief Executive Officer, Howard W. Robin , is scheduled to present at the upcoming Jefferies 2015 Global Healthcare Conference in New York City on Tuesday, June 2, 2015 at 8:30 a.m. Ea
Read more →NKTRNektar Therapeutics Reports Financial Results for the First Quarter of 2015 Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2015. Cash and investments in...
SAN FRANCISCO , April 30, 2015 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial results for the first quarter ended March 31, 2015 . Cash and investments in marketable securities at March 31, 2015 were $325.8 million as compared to $262.8 million
Read more →NKTRNektar Therapeutics Reports Financial Results for the First Quarter of 2015
Therapeutics Reports Financial Results for the FRANCISCO, Calif., April 30, 2015 -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2015. and investments in marketable securities at March 31, 2015 were $325.8 millio
Read more →NKTRNektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2015 on Thursday, April 30, 2015, after...
SAN FRANCISCO , April 23, 2015 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the first quarter ended March 31, 2015 on Thursday, April 30, 2015 , after the close of U.S.-based financial markets. Howard Robin , president and chief exec
Read more →NKTRBaxter Submits Application To Japan's MHLW For Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A Nektar Therapeutics (NASDAQ:NKTR) reported today that partner Baxter International Inc. announced that the company has submitted a new drug...
DEERFIELD, Ill. , April 16, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) reported today that partner Baxter International Inc. announced that the company has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare for the approval of B
Read more →NKTRNektar Therapeutics to Present at the 14th Annual Needham Healthcare Conference Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its corporate presentation at the 14th Annual Needham...
SAN FRANCISCO , April 13, 2015 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that the company will be webcasting its corporate presentation at the 14th Annual Needham Healthcare Conference to be held at the Westin Grand Central Hotel in New York , on Wednesd
Read more →NKTRNektar Announces Receipt of $100 Million Milestone Payment from AstraZeneca Nektar Therapeutics (NASDAQ: NKTR) announced today that it has received a $100 million payment under a license agreement with AstraZeneca. The cash...
SAN FRANCISCO , April 2, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today that it has received a $100 million payment under a license agreement with AstraZeneca. The cash payment under the Nektar-AstraZeneca agreement was triggered by the first commercial
Read more →NKTRMOVANTIK™ (Naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain Launched In The US Nektar Therapeutics (NASDAQ: NKTR) reported that partner AstraZeneca announced today that MOVANTIK™ (naloxegol) has launched in the United States. On ...
WILMINGTON, Del. , March 31, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) reported that partner AstraZeneca announced today that MOVANTIK™ (naloxegol) has launched in the United States . On September 16, 2014 , the US Food and Drug Administration (FDA) approved MOVANT
Read more →NKTRAstraZeneca And Daiichi Sankyo To Jointly Commercialise MOVANTIK In The US Nektar Therapeutics (NASDAQ: NKTR) reported that partner AstraZeneca today announced a co-commercialisation agreement with Daiichi Sankyo, Inc. for...
SAN FRANCISCO , March 19, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) reported that partner AstraZeneca today announced a co-commercialisation agreement with Daiichi Sankyo, Inc. for MOVANTIK™ (naloxegol) in the US, in line with the Company's strategy of delivering v
Read more →NKTREtirinotecan Pegol (NKTR-102) Prolonged Median Overall Survival by 2.1 Months versus Active Control in Patients with Advanced Breast Cancer in Phase 3 Study; Trial Did Not Achieve Statistical Significance (p=0.08) Nektar Therapeutics (NASDAQ: NKTR) today announced topline results from its Phase 3 BEACON study evaluating single-agent NKTR-102 in patients with...
SAN FRANCISCO , March 17, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced topline results from its Phase 3 BEACON study evaluating single-agent NKTR-102 in patients with advanced breast cancer. BEACON compared NKTR-102 to an active control arm comprised o
Read more →NKTRNektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with Chronic Low Back Pain Nektar Therapeutics (NASDAQ: NKTR) today announced the enrollment of the first patient in SUMMIT-07, its initial Phase 3 study of NKTR-181, a...
SAN FRANCISCO , Feb. 25, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced the enrollment of the first patient in SUMMIT-07, its initial Phase 3 study of NKTR-181, a first-in-class, opioid analgesic molecule with a slow rate of entry into the brain. This sl
Read more →NKTRNektar Therapeutics Reports Fourth Quarter and Year-End 2014 Financial Results
Nektar Therapeutics Reports Fourth Quarter and Year-End 2014 Financial Results SAN FRANCISCO, Calif., February 24, 2015 - Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2014. Cash and investments in m
Read more →NKTRNektar Therapeutics Reports Fourth Quarter and Year-End 2014 Financial Results Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2014. Cash and investments ...
SAN FRANCISCO , Feb. 24, 2015 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial results for the fourth quarter and year ended December 31, 2014 . Cash and investments in marketable securities at December 31, 2014 were $262.8 million as compared to
Read more →NKTRNektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2014 on Tuesday, February 24, 2015, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2014 on Tuesday, February...
SAN FRANCISCO , Feb. 17, 2015 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the fourth quarter and year-ended December 31, 2014 on Tuesday, February 24, 2015 , after the close of U.S.-based financial markets. Howard Robin , president
Read more →NKTRBaxter Presents Additional Data From Pivotal Study Of BAX 855, Extended Half-life Investigational Recombinant FVIII Based On ADVATE For Hemophilia A Nektar Therapeutics (NASDAQ:NKTR) reported that partner Baxter International Inc. today presented additional efficacy and safety data from the Phase...
DEERFIELD, Ill. , Feb. 11, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) reported that partner Baxter International Inc. today presented additional efficacy and safety data from the Phase III pivotal study of BAX 855, an investigational, extended half-life recombinant
Read more →NKTRFederal Register / Vol. 80, No. 15 / Friday
Michele M. Leonhart, Administrator. [FR Doc. 2015-01172 Filed 1-22-15; 8:45 am] BILLING CODE 4410-09-P ________________________________ ___ DEPARTMENT OF HOMELAND SECURITY Coast Guard 33 CFR Part 5 [Docket No. USCG-1999-6712] RIN 1625-AB66 Revision of Auxiliary Regulations AGENCY
Read more →NKTRNektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 33rd Annual J.P....
SAN FRANCISCO , Jan. 6, 2015 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) President and Chief Executive Officer, Howard W. Robin , is scheduled to present at the upcoming 33 rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2015 at 11:00
Read more →NKTRNektar Presents Data on Target-Specific Biomarkers from Circulating Tumor Cell Sub-Study of Phase 3 BEACON Study of Etirinotecan Pegol (NKTR-102) in Patients with Advanced Breast Cancer Nektar Therapeutics (NASDAQ: NKTR) today presented biomarker data from a sub-study of the Phase 3 BEACON study of etirinotecan pegol (NKTR-102) which ...
SAN ANTONIO and SAN FRANCISCO , Dec. 11, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today presented biomarker data from a sub-study of the Phase 3 BEACON study of etirinotecan pegol (NKTR-102) which collected and analyzed circulating tumor cell (CTC) samples from pa
Read more →NKTRMOVENTIG® Approved In The European Union For Opioid-Induced Constipation Nektar Therapeutics (NASDAQ:NKTR) reported partner AstraZeneca today announced that MOVENTIG® (naloxegol) has been granted Marketing Authorisation by ...
SAN FRANCISCO , Dec. 9, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) reported partner AstraZeneca today announced that MOVENTIG ® (naloxegol) has been granted Marketing Authorisation by the European Commission (EC) for the treatment of opioid-induced constipation (OIC
Read more →NKTRNektar Presents Preclinical Study Findings for Etirinotecan Pegol (NKTR-102) in Combination with a PARP Inhibitor in BRCA1-deficient Cancer Model Nektar Therapeutics (NASDAQ: NKTR) today announced results of a study investigating the preclinical anti-tumor activity and tolerability of...
SAN FRANCISCO , Nov. 20, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced results of a study investigating the preclinical anti-tumor activity and tolerability of etirinotecan pegol (NKTR-102) in combination with the PARP inhibitor rucaparib in a BRCA1-def
Read more →NKTRNektar Therapeutics Reports Financial Results for the Third Quarter of 2014 Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2014. Cash and investments in...
SAN FRANCISCO , Nov. 6, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial results for the third quarter ended September 30, 2014 . Cash and investments in marketable securities at September 30, 2014 were $261.6 million as compared to $301.4 mi
Read more →NKTRNektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2014 on Thursday, November 6, 2014,...
SAN FRANCISCO , Oct. 30, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the third quarter ended September 30, 2014 on Thursday, November 6, 2014 , after the close of U.S.-based financial markets. Howard Robin , president and chief
Read more →NKTRNektar Therapeutics Announces MOVENTIG® (naloxegol) Receives Positive CHMP Opinion In EU For Treatment Of Adults With Opioid-Induced Constipation Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca announced that the Committee for Medicinal Products for Human Use (CHMP) of ...
SAN FRANCISCO , Sept. 26, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) reported today that partner AstraZeneca announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a
Read more →NKTRNektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting Nektar Therapeutics (NASDAQ:NKTR) today announced results from preclinical studies characterizing the analgesic profiles of a series of the company's ...
SAN FRANCISCO , Sept. 19, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced results from preclinical studies characterizing the analgesic profiles of a series of the company's internally-discovered oral, peripherally-acting kappa opioid receptor agonist mol
Read more →NKTRFDA Approves MOVANTIK™ (naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved...
SAN FRANCISCO , Sept. 16, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK ™ (naloxegol) tablets as the first once-daily oral peripherally-acting mu-op
Read more →NKTRNektar Therapeutics Reports Financial Results for the Second Quarter of 2014 Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2014. Cash and investments in...
SAN FRANCISCO , July 31, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial results for the second quarter ended June 30, 2014 . Cash and investments in marketable securities at June 30, 2014 were $301.4 million as compared to $309.1 million at
Read more →NKTRNektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2014 on Thursday, July 31, 2014, after...
SAN FRANCISCO , July 22, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the second quarter ended June 30, 2014 on Thursday, July 31, 2014 , after the close of U.S.-based financial markets. Howard Robin , president and chief execut
Read more →NKTRData Published in the New England Journal of Medicine Demonstrate that Naloxegol Improved Opioid-Induced Constipation in Chronic Pain Patients Nektar Therapeutics (NASDAQ:NKTR) reported that partner AstraZeneca today announced that the New England Journal of Medicine (NEJM) has published...
SAN FRANCISCO , June 19, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) reported that partner AstraZeneca today announced that the New England Journal of Medicine (NEJM) has published results of two pivotal Phase III studies – KODIAC-4 and KODIAC-5 of naloxegol, an inve
Read more →NKTRUS FDA ADVISORY COMMITTEE RECOMMENDS NO CARDIOVASCULAR OUTCOMES TRIAL FOR PERIPHERALLY-ACTING MU-OPIOID RECEPTOR ANTAGONIST (PAMORA) CLASS INCLUDING MOVANTIK Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca announced that the majority of US Food and Drug Administration (FDA)...
SAN FRANCISCO , June 12, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) reported today that partner AstraZeneca announced that the majority of US Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) members voted that the
Read more →NKTRNektar Therapeutics Stock Trading Halted Today; FDA Advisory Committee to Discuss Peripherally-Acting Opioid Receptor Antagonists Nektar Therapeutics (NASDAQ:NKTR), a biopharmaceutical company developing novel pain and cancer therapeutics, today announced that NASDAQ has halted...
SAN FRANCISCO , June 11, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ), a biopharmaceutical company developing novel pain and cancer therapeutics, today announced that NASDAQ has halted trading of the company's common stock. The U.S. Food and Drug Administration's (FD
Read more →NKTRNektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, at 50th ASCO Meeting Nektar Therapeutics (NASDAQ:NKTR) announced positive preclinical data for NKTR-214, a new investigational cancer immunotherapy which selectively...
SAN FRANCISCO , June 1, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced positive preclinical data for NKTR-214, a new investigational cancer immunotherapy which selectively activates the IL-2 receptor complex and is being developed as a potential treatment for
Read more →NKTRPositive Data from Phase 2 Trial of NKTR-102 in Patients with Avastin®-Refractory High-Grade Glioma Presented at 50th ASCO Meeting Nektar Therapeutics (NASDAQ: NKTR) announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients ...
SAN FRANCISCO , May 31, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute und
Read more →NKTRNektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer Nektar Therapeutics (Nasdaq: NKTR), a biopharmaceutical company developing novel pain and cancer therapeutics, announced that Ivan Gergel, M.D., will ...
SAN FRANCISCO , May 19, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ), a biopharmaceutical company developing novel pain and cancer therapeutics, announced that Ivan Gergel , M.D., will serve as the Company's new Senior Vice President, Drug Development & Chief Medical
Read more →NKTRNektar Therapeutics To Present at the UBS 2014 Global Healthcare Conference in New York City Nektar Therapeutics' (Nasdaq: NKTR) is scheduled to present at the upcoming UBS 2014 Global Healthcare Conference in New York at the Sheraton New...
SAN FRANCISCO , May 16, 2014 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) is scheduled to present at the upcoming UBS 2014 Global Healthcare Conference in New York at the Sheraton New York Hotel on Tuesday, May 20, 2014 at 2:30 p.m. Eastern time . The presentation will b
Read more →NKTRNektar Reports Positive Preclinical Data for Two Oncology Programs at 2014 AACR Nektar Therapeutics (Nasdaq: NKTR), a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer...
SAN FRANCISCO , April 9, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ), a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technologies, today announced that preclinical data for NKTR-102 and NKTR-214 were
Read more →NKTRNektar Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2013. Cash and investments ...
SAN FRANCISCO , Feb. 26, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial results for the fourth quarter and year ended December 31, 2013 . Cash and investments in marketable securities at December 31, 2013 were $262.0 million as compared to
Read more →NKTRNektar to Announce Financial Results for the Fourth Quarter and Year-End of 2013 on Wednesday, February 26, 2014, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2013 on Wednesday, February ...
SAN FRANCISCO , Feb. 19, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the fourth quarter and year-ended December 31, 2013 on Wednesday, February 26, 2014 , after the close of U.S.-based financial markets. Howard Robin , presiden
Read more →NKTRNektar Therapeutics Prices Public Offering of Common Stock Nektar Therapeutics (Nasdaq: NKTR) ( Nektar ) today announced the pricing of its previously announced underwritten public offering of 8,500,000...
SAN FRANCISCO , Jan. 22, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) ("Nektar") today announced the pricing of its previously announced underwritten public offering of 8,500,000 shares of its common stock at a public offering price of $12.75 per share. In connection
Read more →NKTRNektar Therapeutics Announces Public Offering of 8,500,000 Shares of Common Stock Nektar Therapeutics (Nasdaq: NKTR) ( Nektar ) today announced that it has commenced an underwritten public offering of 8,500,000 shares of its common ...
SAN FRANCISCO , Jan. 21, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) ("Nektar") today announced that it has commenced an underwritten public offering of 8,500,000 shares of its common stock. In connection with this offering, Nektar will also grant to the underwriters
Read more →NKTRNektar Presents Positive Clinical Data from a Phase 1 Study of Etirinotecan Pegol (NKTR-102) in Combination with 5-Flourouracil/Leucovorin at the 2014 Gastrointestinal Cancers Symposium Nektar Therapeutics' (Nasdaq: NKTR) presented favorable data today from a Phase 1 study of etirinotecan pegol (EP, NKTR-102) in combination with...
SAN FRANCISCO , Jan. 18, 2014 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) presented favorable data today from a Phase 1 study of etirinotecan pegol (EP, NKTR-102) in combination with 5-fluorouracil (5-FU)/Leucovorin (LV) in patients with advanced cancer. NKTR-102 is the
Read more →NKTREtirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer Nektar Therapeutics (NASDAQ:NKTR) announced today that the Independent Data Monitoring Committee (DMC) created to provide safety oversight for the...
SAN FRANCISCO , Jan. 14, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today that the Independent Data Monitoring Committee (DMC) created to provide safety oversight for the Company's pivotal clinical study for etirinotecan pegol (NKTR-102) has recommended co
Read more →NKTRFirst Subjects Dosed in Phase 1 Clinical Study of NKTR-171, A New Peripherally-Restricted Sodium Channel Blocker to Treat Neuropathic Pain Nektar Therapeutics (Nasdaq: NKTR) today announced that the first subjects were dosed in a Phase 1 clinical study for NKTR-171, a new sodium channel...
SAN FRANCISCO , Jan. 14, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that the first subjects were dosed in a Phase 1 clinical study for NKTR-171, a new sodium channel blocker being developed as an oral therapy for the treatment of peripheral neuropath
Read more →NKTRNektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 32nd Annual J.P....
SAN FRANCISCO , Jan. 8, 2014 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) President and Chief Executive Officer, Howard W. Robin , is scheduled to present at the upcoming 32 nd Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel on Tu
Read more →NKTRNew Drug Application For Naloxegol Accepted By United States Food And Drug Administration Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca announced that the United States Food and Drug Administration (FDA) has...
SAN FRANCISCO , Nov. 19, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) reported today that partner AstraZeneca announced that the United States Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for naloxegol, an investigational peripherally
Read more →NKTRBaxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A Baxter International Inc. today announced it has completed enrollment in its Phase III clinical trial of BAX 855, an investigational extended...
DEERFIELD, Ill. , Nov. 13, 2013 /PRNewswire/ -- Baxter International Inc. today announced it has completed enrollment in its Phase III clinical trial of BAX 855, an investigational extended half-life, recombinant factor VIII (rFVIII) treatment for hemophilia A. The ongoing trial
Read more →NKTRNektar Therapeutics Reports Financial Results for the Third Quarter of 2013 Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2013. Cash and investments in...
SAN FRANCISCO , Nov. 7, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial results for the third quarter ended September 30, 2013 . Cash and investments in marketable securities at September 30, 2013 were $208.6 million as compared to $302.2 mi
Read more →NKTRNektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2013 on Thursday, November 7, 2013,...
SAN FRANCISCO , Oct. 30, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the third quarter ended September 30, 2013 on Thursday, November 7, 2013 , after the close of U.S.-based financial markets. Howard Robin , president and chief
Read more →NKTRNektar and Roswell Park Cancer Institute Announce Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Second-Line Treatment in Patients with Relapsed or Refractory Small Cell Lung Cancer (SCLC) Nektar Therapeutics (NASDAQ:NKTR) and Roswell Park Cancer Institute (RPCI) announced today that the first patients have been dosed in a phase II...
SAN FRANCISCO and BUFFALO, N.Y. , Oct. 24, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) and Roswell Park Cancer Institute (RPCI) announced today that the first patients have been dosed in a phase II investigator-sponsored study of etirinotecan pegol in patients with r
Read more →NKTRNektar Reports on Advancements with Clinical Pipeline and Introduces New Preclinical Candidates at Investor and Analyst R&D Day Nektar Therapeutics (Nasdaq: NKTR) will present an overview of the company's proprietary drug candidate pipeline during the company's R&D Day for...
SAN FRANCISCO , Oct. 8, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will present an overview of the company's proprietary drug candidate pipeline during the company's R&D Day for investors and analysts today from 11:30 a.m. to 4:30 p.m. ET in New York City . Pain ma
Read more →NKTRNektar to Host Investor and Analyst R&D Day in New York City Nektar Therapeutics (Nasdaq: NKTR) will host an Investor and Analyst R&D Day for its institutional investors and research analysts on Tuesday,...
SAN FRANCISCO , Oct. 2, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will host an Investor and Analyst R&D Day for its institutional investors and research analysts on Tuesday, October 8, 2013 from 11:30 a.m. to 4:30 p.m. ET in New York City . Howard Robin , Presiden
Read more →NKTRNektar Announces Preliminary Topline Results from Phase 2 Efficacy Study for NKTR-181 in Chronic Pain Patients with Osteoarthritis of the Knee Nektar Therapeutics (Nasdaq: NKTR) announced the preliminary topline results from a Phase 2 study of NKTR-181 for the treatment of moderate-to-severe ...
SAN FRANCISCO , Sept. 26, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced the preliminary topline results from a Phase 2 study of NKTR-181 for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis of the knee. The Phase 2 study utiliz
Read more →NKTRNektar Therapeutics Reports Financial Results for the Second Quarter of 2013 Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2013. Cash and investments in...
SAN FRANCISCO , Aug. 8, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial results for the second quarter ended June 30, 2013 . Cash and investments in marketable securities at June 30, 2013 were $226.9 million . "I am very pleased with Nektar
Read more →NKTRNektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer SAN FRANCISCO, July 30, 2013 /PRNewswire/-- Nektar Therapeutics (NASDAQ:NKTR) today announced that enrollment is complete in the pivotal clinical...
SAN FRANCISCO , July 30, 2013 /PRNewswire/-- Nektar Therapeutics (NASDAQ: NKTR ) today announced that enrollment is complete in the pivotal clinical study of etirinotecan pegol (NKTR-102) in patients with metastatic breast cancer. The Phase 3 study, also known as the BEACON trial
Read more →NKTRNektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence Nektar Therapeutics (Nasdaq: NKTR) today announced positive top-line results from a human abuse liability (HAL) study for NKTR-181, a first-in-class, ...
SAN DIEGO , June 19, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced positive top-line results from a human abuse liability (HAL) study for NKTR-181, a first-in-class, opioid analgesic molecule with a slow rate of entry into the brain. This slow rate of e
Read more →NKTRNektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting Nektar Therapeutics (NASDAQ:NKTR) announced positive preclinical data for NKTR-214, an investigational cancer immunotherapy which targets the IL-2...
SAN FRANCISCO , June 3, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced positive preclinical data for NKTR-214, an investigational cancer immunotherapy which targets the IL-2 receptor complex and is being developed as a potential treatment for multiple cancers.
Read more →NKTRNektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting Nektar Therapeutics (NASDAQ:NKTR) announced today that it presented a series of target-specific biomarkers that are being evaluated in the...
CHICAGO and SAN FRANCISCO , June 1, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today that it presented a series of target-specific biomarkers that are being evaluated in the development of etirinotecan pegol for the treatment of breast cancer. Etirinotecan
Read more →NKTRNektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 2013 Jefferies...
SAN FRANCISCO , May 30, 2013 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) President and Chief Executive Officer, Howard W. Robin , is scheduled to present at the upcoming 2013 Jefferies Global Healthcare Conference in New York at the Grand Hyatt Hotel on Tuesday, June 4,
Read more →NKTRNektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 2013 UBS Global...
SAN FRANCISCO , May 16, 2013 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) President and Chief Executive Officer, Howard W. Robin , is scheduled to present at the upcoming 2013 UBS Global Healthcare Conference in New York at the Sheraton New York Hotel on Tuesday, May 21,
Read more →NKTRNektar Therapeutics Reports Financial Results for the First Quarter of 2013 Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2013. Cash and investments in...
SAN FRANCISCO , May 9, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial results for the first quarter ended March 31, 2013 . Cash and investments in marketable securities at March 31, 2013 were $261.2 million as compared to $302.2 million at
Read more →NKTRNektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2013 on Thursday, May 9, 2013, after the ...
SAN FRANCISCO , May 2, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the first quarter ended March 31, 2013 on Thursday, May 9, 2013 , after the close of U.S.-based financial markets. Howard Robin , president and chief executive
Read more →NKTRPositive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013 Nektar Therapeutics (Nasdaq: NKTR) today presented positive preclinical data for NKTR-214, a novel cancer immunotherapy which targets the IL-2...
SAN FRANCISCO , April 7, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today presented positive preclinical data for NKTR-214, a novel cancer immunotherapy which targets the IL-2 receptor complex, at the 2013 American Association for Cancer Research (AACR) Annual Meeti
Read more →NKTRNektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2012. Cash, cash...
SAN FRANCISCO , Feb. 28, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial results for the fourth quarter and year ended December 31, 2012 . Cash, cash equivalents, and investments at December 31, 2012 were $302.2 million as compared to $414.9
Read more →NKTRAstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation AstraZeneca today announced high-level results from KODIAC-08, an open-label, randomised, 52-week, long-term safety trial of naloxegol versus usual...
SAN FRANCISCO , Feb. 26, 2013 /PRNewswire/ -- AstraZeneca today announced high-level results from KODIAC-08, an open-label, randomised, 52-week, long-term safety trial of naloxegol versus usual care (UC) in patients with non-cancer related pain and opioid-induced constipation (OI
Read more →NKTRNektar to Announce Financial Results for the Fourth Quarter and Year-End of 2012 On Thursday, February 28, 2013, After Close of U.S.-Based Financial Markets Nektar Therapeutics (NASDAQ:NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2012 on Thursday, February...
SAN FRANCISCO , Feb. 13, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) will announce its financial results for the fourth quarter and year-ended December 31, 2012 on Thursday, February 28, 2013 , after the close of U.S.-based financial markets. Howard Robin , president
Read more →NKTRNektar Announces Initiation of Investigator-Initiated Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Third-Line Treatment in Patients with Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC) Nektar Therapeutics (NASDAQ:NKTR) announced today the start of a Phase 2 investigator-initiated study of etirinotecan pegol in patients with...
SAN FRANCISCO , Feb. 5, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today the start of a Phase 2 investigator-initiated study of etirinotecan pegol in patients with metastatic and recurrent NSCLC. The study is being conducted at the Abramson Cancer Center o
Read more →NKTRNektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 31st Annual J.P....
SAN FRANCISCO , Jan. 4, 2013 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) President and Chief Executive Officer, Howard W. Robin , is scheduled to present at the upcoming 31st Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel on Wed
Read more →NKTRAstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation AstraZeneca today announced positive top-line results from two Phase III trials and one safety extension trial in patients with non-cancer related...
SAN FRANCISCO , Nov. 12, 2012 /PRNewswire/ -- AstraZeneca today announced positive top-line results from two Phase III trials and one safety extension trial in patients with non-cancer related pain and opioid-induced constipation (OIC). These Phase III KODIAC trials evaluated the
Read more →NKTRNektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol Nektar Therapeutics (Nasdaq: NKTR) will host a conference call with investors to discuss the positive Phase 3 clinical results announced by its...
SAN FRANCISCO , Nov. 12, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will host a conference call with investors to discuss the positive Phase 3 clinical results announced by its partner AstraZeneca. Howard Robin , president and chief executive officer, will host the
Read more →NKTRNektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer Nektar Therapeutics (NASDAQ:NKTR) announced today that the U.S. Food and Drug Administration (FDA) has designated etirinotecan pegol (NKTR-102) as a...
SAN FRANCISCO , Nov. 7, 2012 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today that the U.S. Food and Drug Administration (FDA) has designated etirinotecan pegol (NKTR-102) as a Fast Track development program for the treatment of patients with locally recurrent
Read more →NKTRNektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2012 on Tuesday, November 13, 2012,...
SAN FRANCISCO , Nov. 6, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the third quarter ended September 30, 2012 on Tuesday, November 13, 2012 , after the close of U.S.-based financial markets. Howard Robin , president and chief
Read more →NKTRNektar Presents Positive Preclinical Data for NKTR-171, A Novel Sodium Channel Blocker to Treat Neuropathic Pain, at 41st Annual Meeting of the Society for Neuroscience Nektar Therapeutics (Nasdaq: NKTR) today announced that preclinical data for NKTR-171, a new investigational drug candidate to treat neuropathic...
SAN FRANCISCO , Oct. 15, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that preclinical data for NKTR-171, a new investigational drug candidate to treat neuropathic pain, was presented at the 41 st Annual Meeting of the Society for Neuroscience: Neurosc
Read more →NKTRNKTR-192, A New Short-Acting Mu-Opioid Analgesic Molecule, Achieves Desired Pharmacokinetic Profile in First Phase 1a Clinical Study Nektar Therapeutics (Nasdaq: NKTR) announced today that positive data from the first single-ascending dose Phase 1a clinical study of NKTR-192, the...
SAN FRANCISCO , Sept. 18, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that positive data from the first single-ascending dose Phase 1a clinical study of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate, demonstrate that the dru
Read more →NKTRNektar Therapeutics' President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming UBS 2012 Global...
SAN FRANCISCO , Sept. 13, 2012 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) President and Chief Executive Officer, Howard W. Robin , is scheduled to present at the upcoming UBS 2012 Global Life Sciences Conference in New York at the Grand Hyatt Hotel on Wednesday, Septemb
Read more →NKTRNektar Therapeutics Reports Financial Results for the Second Quarter of 2012 Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2012. Cash, cash equivalents, and...
SAN FRANCISCO , Aug. 9, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial results for the second quarter ended June 30, 2012 . Cash, cash equivalents, and investments at June 30, 2012 were $477.1 million as compared to $498.8 million at March
Read more →NKTRNektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma Nektar Therapeutics (NASDAQ:NKTR) announced today the start of a Phase 2 study of etirinotecan pegol in patients with bevacizumab (Avastin)-resistant ...
SAN FRANCISCO , Aug. 7, 2012 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today the start of a Phase 2 study of etirinotecan pegol in patients with bevacizumab (Avastin)-resistant high-grade glioma being conducted at Stanford Cancer Institute. The Phase 2 study i
Read more →NKTRNektar to Announce Financial Results for the Second Quarter of 2012 On Thursday, August 9, 2012, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2012 on Thursday, August 9, 2012, after...
SAN FRANCISCO, Calif. , Aug. 2, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the second quarter ended June 30, 2012 on Thursday, August 9, 2012 , after the close of U.S.-based financial markets. Howard Robin , president and chie
Read more →NKTRNektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain Nektar Therapeutics (NASDAQ: NKTR) announced today that the first patient has been enrolled in a Phase 2 clinical study of NKTR-181, a new,...
SAN FRANCISCO , July 24, 2012 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today that the first patient has been enrolled in a Phase 2 clinical study of NKTR-181, a new, first-of-its-kind, opioid analgesic candidate. NKTR-181 is a novel mu-opioid agonist molecule
Read more →NKTRNektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017 Nektar Therapeutics (Nasdaq: NKTR) today announced the private placement of $125 million of 12.0% Senior Secured Notes Due in 2017 in an offering...
SAN FRANCISCO , July 10, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced the private placement of $125 million of 12.0% Senior Secured Notes Due in 2017 in an offering exempt from the registration requirements of the Securities Act of 1933. Nektar intends
Read more →NKTRNektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain Nektar Therapeutics (NASDAQ:NKTR) announced today that the U.S. Food and Drug Administration (FDA) has designated NKTR-181 as a Fast Track...
SAN FRANCISCO , June 7, 2012 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today that the U.S. Food and Drug Administration (FDA) has designated NKTR-181 as a Fast Track development program for the treatment of moderate to severe chronic pain. NKTR-181 is a novel
Read more →NKTRNektar Therapeutics Reports Financial Results for the First Quarter of 2012 Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2012. Cash, cash equivalents, and...
SAN FRANCISCO , May 2, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial results for the first quarter ended March 31, 2012 . Cash, cash equivalents, and investments at March 31, 2012 were $498.8 million as compared to $414.9 million at Decemb
Read more →NKTRNektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2012 on Wednesday, May 2, 2012, after...
SAN FRANCISCO , April 25, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the first quarter ended March 31, 2012 on Wednesday, May 2, 2012 , after the close of U.S.-based financial markets. Howard Robin , president and chief execut
Read more →NKTRNektar to Host Investor and Analyst R&D Day in New York City Nektar Therapeutics (Nasdaq: NKTR) will host an Investor and Analyst R&D Day for its institutional investors and research analysts on Monday, April...
SAN FRANCISCO , April 10, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will host an Investor and Analyst R&D Day for its institutional investors and research analysts on Monday, April 16, 2012 from 12:00 p.m. to 5:00 p.m. ET in New York City . The meeting will focus o
Read more →NKTRNektar Doses First Subjects in Phase 1 Clinical Study Evaluating NKTR-192, a New Short-Acting Opioid Molecule for the Treatment of Acute Pain Nektar Therapeutics (Nasdaq: NKTR) announced today that the first subjects were dosed last week in a Phase 1 clinical study to evaluate the...
SAN FRANCISCO , April 2, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that the first subjects were dosed last week in a Phase 1 clinical study to evaluate the pharmacokinetics and safety of NKTR-192, the company's novel short-acting mu-opioid analgesic
Read more →NKTRNektar Reports that Partner Affymax Has Announced FDA Approval of OMONTYS® (Peginesatide) Injection for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis Nektar Therapeutics (NASDAQ: NKTR) today reported that its partner Affymax, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
SAN FRANCISCO , March 28, 2012 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today reported that its partner Affymax, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved OMONTYS® (peginesatide) Injection for the treatment of anemia due to chronic ki
Read more →NKTRNektar Therapeutics Announces Webcast of Presentation at the 32nd Annual Cowen and Company Healthcare Conference in Boston Nektar Therapeutics (Nasdaq: NKTR) today announced that it will webcast its presentation at the 32nd Annual Cowen and Company Healthcare Conference...
SAN FRANCISCO , March 2, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that it will webcast its presentation at the 32nd Annual Cowen and Company Healthcare Conference to be held at the Boston Marriott Copley Place on Tuesday, March 6, 2012 at 10:00 a.m
Read more →NKTRNektar Therapeutics Announces Agreement to Sell CIMZIA® and MIRCERA® Royalties to Royalty Pharma for $124 Million Nektar Therapeutics (Nasdaq: NKTR) today announced that it agreed to sell to Royalty Pharma its royalties on future sales of CIMZIA®, under Nektar's...
SAN FRANCISCO , Feb. 29, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that it agreed to sell to Royalty Pharma its royalties on future sales of CIMZIA®, under Nektar's agreement with UCB Pharma, and MIRCERA®, under Nektar's agreement with Roche. In con
Read more →NKTRNektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) today announced a presentation of positive clinical data for NKTR-181, its new oral opioid analgesic molecule, at...
SAN FRANCISCO , Feb. 27, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced a presentation of positive clinical data for NKTR-181, its new oral opioid analgesic molecule, at the 2012 American Academy of Pain Medicine's 28th Annual Meeting (AAPM). NKTR-181 is
Read more →NKTRNektar to Announce Financial Results for the Fourth Quarter and Year-End of 2011 on Wednesday, February 29, 2012, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter ended December 31, 2011 on Wednesday, February 29,...
SAN FRANCISCO, Calif. , Feb. 24, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the fourth quarter ended December 31, 2011 on Wednesday, February 29, 2012 , after the close of U.S.-based financial markets. Howard Robin , president
Read more →NKTRBaxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A Baxter International Inc. today announced the dosing of the first patients in a Phase I clinical trial of its lead investigational candidate, BAX...
DEERFIELD, Ill. , Jan. 5, 2012 /PRNewswire/ -- Baxter International Inc. today announced the dosing of the first patients in a Phase I clinical trial of its lead investigational candidate, BAX 855, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII)
Read more →NKTRNektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 30th Annual J.P....
SAN FRANCISCO , Jan. 4, 2012 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) President and Chief Executive Officer, Howard W. Robin , is scheduled to present at the upcoming 30th Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel on Wed
Read more →NKTRNektar Reports Affymax Announced FDA Advisory Committee Voted in Favor of Benefit/Risk Profile for Peginesatide for Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis Nektar Therapeutics (NASDAQ:NKTR) today reported that its partner Affymax, Inc. announced that the U.S. Food and Drug Administration (FDA) Oncologic...
SAN FRANCISCO , Dec. 8, 2011 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today reported that its partner Affymax, Inc. announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 15 to 1, with 1 abstention, that peginesatide
Read more →NKTRPositive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 Nektar Therapeutics (NASDAQ: NKTR) announced today that positive preclinical data for NKTR-192, a novel mu-opioid agonist, was presented at the 41st...
SAN FRANCISCO and WASHINGTON , Nov. 14, 2011 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today that positive preclinical data for NKTR-192, a novel mu-opioid agonist, was presented at the 41st Annual Meeting of the Society for Neuroscience being held November 12
Read more →NKTRNektar Therapeutics Reports Third Quarter 2011 Financial Results Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2011. Cash, cash equivalents, and...
SAN FRANCISCO, Calif. , Nov. 2, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial results for the third quarter ended September 30, 2011 . Cash, cash equivalents, and investments at September 30, 2011 were $458.0 million as compared to $315.9
Read more →NKTRNektar to Announce Financial Results for the Third Quarter of 2011 on Wednesday, November 2, 2011, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2011 on Wednesday, November 2, 2011, ...
SAN FRANCISCO , Oct. 26, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the third quarter ended September 30, 2011 on Wednesday, November 2, 2011 , after the close of U.S.-based financial markets. Howard Robin , president and chie
Read more →NKTRNektar Presents Positive Data for Novel Opioid Analgesic, NKTR-181, at the 2011 American Academy of Pain Management Annual Meeting Nektar Therapeutics (NASDAQ:NKTR) today announced that positive proof-of-concept data is being presented from its first Phase 1 clinical trial of...
SAN FRANCISCO , Sept. 21, 2011 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) today announced that positive proof-of-concept data is being presented from its first Phase 1 clinical trial of NKTR-181 at the American Academy of Pain Management (AAPM) 22nd Annual Clinical Meeti
Read more →NKTRNektar Therapeutics' President and CEO, Howard W. Robin, to Present at the UBS 2011 Global Life Sciences Conference in New York City Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming UBS 2011 Global...
SAN FRANCISCO , Sept. 14, 2011 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) President and Chief Executive Officer, Howard W. Robin , is scheduled to present at the upcoming UBS 2011 Global Life Sciences Conference in New York at the Grand Hyatt Hotel on Tuesday, September
Read more →NKTRPositive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium Nektar Therapeutics (Nasdaq: NKTR) announced today that positive results from the company's Phase 2 clinical study of NKTR-102 in patients with...
SAN FRANCISCO , Sept. 9, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that positive results from the company's Phase 2 clinical study of NKTR-102 in patients with metastatic breast cancer were presented at the ASCO 2011 Breast Cancer Symposium in San F
Read more →NKTRNektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain Nektar Therapeutics (Nasdaq: NKTR) today announced that dosing began in a Phase 1 clinical study to evaluate multiple ascending doses of NKTR-181,...
SAN FRANCISCO , Sept. 8, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that dosing began in a Phase 1 clinical study to evaluate multiple ascending doses of NKTR-181, the company's novel opioid analgesic drug candidate. NKTR-181 is in development as a o
Read more →NKTRNektar Therapeutics Reports Second Quarter 2011 Financial Results Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2011. Cash, cash equivalents, and...
SAN FRANCISCO , Aug. 4, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial results for the second quarter ended June 30, 2011 . Cash, cash equivalents, and investments at June 30, 2011 were $481.8 million as compared to $315.9 million at Decemb
Read more →NKTRNektar to Announce Financial Results for the Second Quarter of 2011 on Thursday, August 4, 2011, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2011 on Thursday, August 4, 2011, after...
SAN FRANCISCO , July 27, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the second quarter ended June 30, 2011 on Thursday, August 4, 2011 , after the close of U.S.-based financial markets. Howard Robin , president and chief execu
Read more →NKTRData from Phase 1 Study of NKTR-181 Demonstrate Proof-of-Concept for Nektar's Novel Opioid Analgesic Candidate Nektar Therapeutics (NASDAQ:NKTR) announced today positive interim data from an ongoing single-dose Phase 1 clinical trial evaluating NKTR-181, the...
SAN FRANCISCO , June 7, 2011 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) announced today positive interim data from an ongoing single-dose Phase 1 clinical trial evaluating NKTR-181, the company's novel mu-opioid analgesic candidate. Interim study results show that the mo
Read more →NKTRNKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a subpopulation of patients in a Phase 2 clinical study evaluating...
CHICAGO , June 5, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced positive results from a subpopulation of patients in a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian cancer. A total of 33 wome
Read more →NKTRNKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 as a second- and...
CHICAGO and SAN FRANCISCO , June 4, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 as a second- and third-line treatment in patients with metastatic breast cancer during the
Read more →NKTRNektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting Nektar Therapeutics (Nasdaq: NKTR) today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in...
SAN FRANCISCO , May 18, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in multiple cancer indications, have been selected for presentation at the 47th Annual Me
Read more →NKTRNektar Therapeutics Reports First Quarter 2011 Financial Results Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the quarter ended March 31, 2011. Cash, cash equivalents, and short-term...
SAN FRANCISCO , April 27, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial results for the quarter ended March 31, 2011 . Cash, cash equivalents, and short-term investments at March 31, 2011 were $518.6 million as compared to $315.9 million a
Read more →NKTRFDA Grants Orphan Drug Designation for Nektar's Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer Nektar Therapeutics (Nasdaq: NKTR) today announced that the company's oncology drug candidate, NKTR-102, has been granted orphan drug status for the...
SAN FRANCISCO , April 21, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that the company's oncology drug candidate, NKTR-102, has been granted orphan drug status for the treatment of women with ovarian cancer by the U.S. Food and Drug Administration (FD
Read more →NKTRNektar to Announce Financial Results for the First Quarter of 2011 on Wednesday, April 27, 2011, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2011 on Wednesday, April 27, 2011, after ...
SAN FRANCISCO , April 18, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the first quarter ended March 31, 2011 on Wednesday, April 27, 2011 , after the close of U.S.-based financial markets. Howard Robin , president and chief exe
Read more →NKTRNektar Initiates Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Pain Nektar Therapeutics (Nasdaq: NKTR) today announced that the first subjects were dosed in a new Phase 1 clinical study to evaluate NKTR-181, the...
SAN FRANCISCO , March 21, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that the first subjects were dosed in a new Phase 1 clinical study to evaluate NKTR-181, the company's next-generation opioid analgesic candidate. NKTR-181 is being developed to eff
Read more →NKTRNektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2010. Cash, cash...
SAN FRANCISCO , March 1, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial results for the fourth quarter and year ended December 31, 2010 . Cash, cash equivalents, and short-term investments at December 31, 2010 were $315.9 million . The cash
Read more →NKTRNektar Therapeutics' President and CEO Howard W. Robin to Present at the 31st Annual Cowen and Company Healthcare Conference in Boston Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the 31st Annual Cowen and...
SAN FRANCISCO , March 1, 2011 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) President and Chief Executive Officer, Howard W. Robin , is scheduled to present at the 31st Annual Cowen and Company Healthcare Conference at the Boston Marriott Copley Place on Tuesday, March 8,
Read more →NKTRNektar to Announce Financial Results for the Fourth Quarter and Year-End of 2010 on Tuesday, March 1, 2011, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter ended December 31, 2010 on Tuesday, March 1, 2011,...
SAN FRANCISCO , Feb. 17, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the fourth quarter ended December 31, 2010 on Tuesday, March 1, 2011 , after the close of U.S.-based financial markets. Howard Robin , president and chief exe
Read more →NKTRNektar Therapeutics Completes Public Offering of Common Stock Nektar Therapeutics (Nasdaq: NKTR) today announced the completion of a public offering of 19,000,000 shares of its common stock. All of the shares...
SAN FRANCISCO , Jan. 24, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced the completion of a public offering of 19,000,000 shares of its common stock. All of the shares were offered by Nektar Therapeutics. The net proceeds to Nektar Therapeutics from the
Read more →NKTRNektar Therapeutics Prices Public Offering of Common Stock Nektar Therapeutics (Nasdaq: NKTR) today announced the pricing of a firm commitment underwritten public offering of 19,000,000 shares of its common...
SAN FRANCISCO , Jan. 19, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced the pricing of a firm commitment underwritten public offering of 19,000,000 shares of its common stock. The public offering is expected to close on or about January 24, 2011 , subjec
Read more →NKTRNektar Therapeutics Announces Proposed Public Offering of Common Stock Nektar Therapeutics (Nasdaq: NKTR) today announced that it is offering to sell shares of its common stock in a firm commitment underwritten public...
SAN FRANCISCO , Jan. 18, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that it is offering to sell shares of its common stock in a firm commitment underwritten public offering. Jefferies & Company, Inc. is acting as sole book-running manager in this off
Read more →NKTRNektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 29th Annual J.P....
SAN FRANCISCO , Jan. 5, 2011 / PRNewswire / -- Nektar Therapeutics' (Nasdaq: NKTR ) President and Chief Executive Officer, Howard W. Robin , is scheduled to present at the upcoming 29th Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel on T
Read more →NKTRNKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in patients with...
SAN ANTONIO , and SAN FRANCISCO , Dec. 12, 2010 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in patients with metastatic breast cancer during the 33rd Annual CTRC-AACR
Read more →NKTRPhase 2 Clinical Data on NKTR-102 in Metastatic Breast Cancer to Be Presented at 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium Nektar Therapeutics (Nasdaq: NKTR) today announced that new Phase 2 clinical data from its study of single-agent NKTR-102 in metastatic breast cancer ...
SAN FRANCISCO , Dec. 9, 2010 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that new Phase 2 clinical data from its study of single-agent NKTR-102 in metastatic breast cancer patients will be presented at the 33rd Annual CTRC-AACR San Antonio Breast
Read more →NKTRNektar Announces Two Preclinical Data Presentations at Society for Neuroscience 40th Annual Meeting: Neuroscience 2010 Nektar Therapeutics (Nasdaq: NKTR) today presented two poster presentations during the Blood-Brain Barrier Session at the Society for Neuroscience...
SAN CARLOS, Calif. , Nov. 13, 2010 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) today presented two poster presentations during the Blood-Brain Barrier Session at the Society for Neuroscience 40th Annual Meeting in San Diego, CA. New data from preclinical models
Read more →NKTRNektar Therapeutics Reports Third Quarter 2010 Financial Results Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2010. Cash, cash equivalents, and...
SAN CARLOS, Calif. , Nov. 4 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial results for the third quarter ended September 30, 2010 . Cash, cash equivalents, and short-term investments at September 30, 2010 were $303.3 million as compare
Read more →NKTRNektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2010 on Thursday, November 4, 2010,...
SAN CARLOS, Calif. , Oct. 28 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the third quarter ended September 30, 2010 on Thursday, November 4, 2010 , after the close of U.S.-based financial markets. Howard Robin , president
Read more →NKTRNektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010 Nektar Therapeutics (Nasdaq: NKTR) today presented new preclinical data demonstrating that NKTR-181, a mu-opioid analgesic with a novel molecular...
SAN CARLOS, Calif. , Oct. 17 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today presented new preclinical data demonstrating that NKTR-181, a mu-opioid analgesic with a novel molecular structure, dramatically reduces abuse liability while providing analgesia comparable to
Read more →NKTRNKTR-181, A Mu-Opioid Analgesic With a Novel Molecular Structure, Demonstrates Slower Entry Rate Into the Brain and Reduced CNS Side Effects Nektar Therapeutics (Nasdaq: NKTR) presented promising data today from preclinical studies of NKTR-181, a next-generation mu-opioid analgesic...
SAN CARLOS, Calif. , Oct.15 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) presented promising data today from preclinical studies of NKTR-181, a next-generation mu-opioid analgesic candidate with a novel molecular design. NKTR-181 is being developed to effectively treat pai
Read more →NKTRNektar Therapeutics To Present at the UBS 2010 Global Life Sciences Conference Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming UBS 2010 Global...
SAN CARLOS, Calif. , Sept. 18 /PRNewswire-FirstCall/ -- Nektar Therapeutics' (Nasdaq: NKTR ) President and Chief Executive Officer, Howard W. Robin , is scheduled to present at the upcoming UBS 2010 Global Life Sciences Conference in New York at the Grand Hyatt Hotel on Tuesday,
Read more →Competitive Position
How NKTR ranks across every disease it competes inCompetitive Position is a premium feature
See how NKTR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial